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Mass spectrometry (MS) coupled with liquid or gas chromatographic 
separation has been widely used in metabolomics studies. With the 
recent advance in the resolution and scan speed of instruments, 
thousands of metabolites can be quantified simultaneously with high 
accuracy. 
In a typical MS-based untargeted metabolomics study, mass-to-
charge ratio (m/z), retention time (RT) and peak area/apex (intensity) 
are measured for Precursor Ions. After the analysis of the precursors 
across samples, the ones of interest are selected for further 
identification and analysis. In this setup, the analysis highly depends on 
robust peak extraction, accurate cross sample RT-m/z alignment and 
reliable normalization of the extracted intensities. Shortcomings in 
these steps can introduce false positive findings due to misalignments 
and erroneous normalization adjustments in data sets with large 
sample size. 
To address the above issues, we developed a software package 
“MetTailor” containing two novel post-alignment data preprocessing 
steps. The first step is to re-aligned the potential misaligned peaks 
using dynamic block summarisation (DBS) method. In addition, we also 
provided a tool to check the re-aligned peaks by extracting isotopic 
intensity patterns from the raw data and comparing the charge and 
isotopic ratio of the re-aligned peaks. The second step is to normalize 
the data using gaussian based weighted kernel function to adjust the 
temporal variation along the RT, where optimal parameters of the 
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kernel function can be automatically determined. This piece of work 
has been published in Bioinformatics. 
Besides Precursor Ions, data dependent acquisition (DDA) and 
data independent acquisition (DIA) are the two methods to produce 
Tandem Mass Spectrometry (MS/MS) spectra (fragments of Precursor 
Ions). In DDA mode, only pre-defined precursors are selected for 
further fragmentation. Conversely, MS/MS spectra from the complete 
precursor mass range are collected in DIA mode. In practice, the 
system sets small sequentially isolate windows of certain width. All the 
precursors within the isolation window have equal chance to get 
fragmented and analysed. However, compared to MS-based 
proteomics, there is a lack of computational algorithms/pipelines to 
analyse MS/MS data in both DDA and DIA modes.
In the second project, we developed a novel data processing 
framework “MetaboDIA” for both consensus MS/MS library construction 
and data extraction from DIA data. In “MetaboDIA”,  we first assigned 
putative molecular formulae to precursor by querying the charge 
deconvoluted mass against a database of known compounds. We then 
constructed compound identification units (CIUs) by RT-aligning the 
precursor peaks with same putative formula across samples, so that 
there was potential unique compound for each CIU. We then 
constructed consensus MS/MS spectral library based on the 
reproducibly for each CIU with rigorous quality control steps (library 
can be built from DDA or DIA data). The library is then used to perform 
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extraction of transition-level peak intensities from DIA data. This piece 
of work is accepted by Analytical Chemistry. 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Chapter 1: Introduction
1.1. Motivation 
For the past decades, the basic working assumption has been that 
illnesses/phenotypes are caused by genetic variations. Plenty of 
population-based genetic studies with large sample sizes have been 
conducted to identify the genetic loci such as Single Nucleotide 
Polymorphism (SNP), DNA insertions and deletions that collectively 
confer susceptibility to diseases or other human traits [1, 2]. Despite 
successful applications of genome-wide data in the form of Genome 
Wide Association Studies (GWAS) as well as whole exome or whole 
genome Sequence studies, clinically interesting phenotypes are often 
partially explained by genetic variations [3, 4], and this prompted 
biomedical researches to pay more attention to other molecules such 
as proteins, small molecules (metabolites), and lipids as well as the 
regulatory connections and interactions among those molecules, with 
the aim to explore novel causality beyond genomics. In this thesis, we 
develop data analytics approaches to address some key issues 
currently present in the field of metabolomics, the study of metabolites. 
Metabolites include not only the intermediate or end products of 
biochemical processes which are derived/biosynthesised from certain 
gene/genes within the cell, but also the molecules directly intake from 
environment or produced by other microorganism. They are involved in 
many biological functions such as cell singling, energy storage and 
structural component of the cell organelle. Furthermore, metabolites 
have been considered as proximal reporters of the health status of a 
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person because their abundances are often directly related to 
pathogenic mechanisms [5]. One major focus in metabolomics is to 
identify novel and early biomarkers of diseases, especially for those 
that are generally diagnosed in the later stages. With the advance in 
technology, researchers have found early metabolic indicators of 
diseases years before apparent symptoms are developed, for example, 
in pancreatic cancer [6], type 2 diabetes [7-9], memory impairment [10], 
and many other conditions. Besides biomarker discovery, 
metabolomics has the potential to help the stratification of disease 
subtypes. Researchers have shown that most complex diseases such 
as cancers are heterogeneous on the molecular level. Therefore, it is 
critical to discover the biomarkers that can differentiate disease 
subtypes at the molecular level and potentially improve outcome of 
treatment. Recent metabolomics studies have shown successful 
findings in rheumatoid arthritis [11], type 2 diabetes [12], Alzheimer's 
disease [13, 14] and other diseases.
In summary, metabolites are important group of molecules. With 
the researches described in this thesis, we addressed a few pressing 
challenges in the metabolomics clinical studies. 
1.2. Mass spectrometry as a technology for metabolite 
identification and relative quantification
Mass spectrometry (MS) technology has been extensively advanced 
during the past decade and it is now the most widely used instrument 
for large-scale profiling of proteins and metabolites. Its high sensitivity 
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and low limit of detection make it an excellent platform for 
metabolomics analysis. MS generates peak data for automated 
detection and quantification of hundreds to thousands of metabolites, 
and is thus expected to enable quantitative analysis of metabolites 
across different experimental conditions. In a typical MS experiment, 
the metabolites are first ionised, for example by electrospray.  These 
ions are then sorted by their mass-to-charge Ratios (m/z) by 
accelerating and subjecting them to a magnetic/electric field. The 
quantification of the ions is represented by the counts at the same m/z 
value. The raw spectral data are stored as spectra with peak intensities 
(counts of ions) of detected ions at different mass-to-charge Ratios. 
The m/z values of the ions can be converted into neutral mass for each 
peak and compound identity can be assigned to the peaks via search 
against a database of known metabolites, whereas the extracted ion 
chromatogram, a series of peaks representing the same compound, 
can be quantified by area-under-the-curve integration and these 
quantitative summary measures can be used for relative sample group 
comparisons in the downstream analysis.
In metabolomics studies, MS is typically coupled with liquid 
chromatographic (LC) or gas chromatographic (GC) separation . In this 
thesis, I focus on the LC-MS setting, which is more commonly used in 
metabolomics studies. Metabolites with different physical/chemical 
properties will be separated and elute at different retention time (RT) 
intervals. This provides an additional separation step before MS 
analysis. Besides precursor (MS1) m/z, the identification of the 
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metabolites can be made more rigorous by producing unique 
fragmentation pattern for each compound, which can be obtained by 
tandem mass spectra (MS/MS).  In tandem mass spectrometry, there 
are several steps. First, the Precursor Ions of a particular m/z value or 
within a specific m/z range (elaborated below) are selected. Next, the 
selected ion/ions are fragmented by collision-induced dissociation or 
other mechanisms. The resulting fragment ions are then detected and 
measured by the second mass scans. In some instrument setups, the 
re-fragmentation of product ions can be performed recursively to the n-
th cycle, which is called sequential mass spectrometry (MSn) [15].
MS/MS data can be generated in two different ways, depending 
on how the Precursor Ions are selected for further fragmentation: data-
dependant acquisition (DDA) and data-independent acquisition (DIA) 
[16]. In DDA mode, Precursor Ions of specific m/z values are isolated 
(usually the top n abundant Precursor Ions). The number of selected 
ions n is the number of MS/MS scans between the adjacent MS1 
scans, and this number is limited by the scan speed of the MS 
instrument. As a result, in the DDA mode, only a small subset of the 
precursors can be fragmented and measured. On the other hand, each 
MS/MS spectrum is expected to show specific fragmentation pattern for 
each Precursor Ion, an important cue for molecular identification. 
Furthermore, dynamic exclusion is usually programmed in the 
instrument setup, which precludes the same precursor from being 
repeatedly fragmented in consecutive MS1 scans beyond a certain 
frequency. This setting has the advantage that fragmentation can be 
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applied to a greater number of Precursor Ions and therefore more 
compounds can be identified. However, ion chromatograms (elution 
profile) of MS/MS fragment ions cannot be constructed and peak areas 
are coarsely estimated for quantification, if possible at all. 
Recently, the DIA mode of scans has been implemented in 
advanced time-of-flight and orbitrap instruments, where the entire MS1 
precursor m/z range is divided into small isolation windows (e.g. 4 to 25 
dalton) [16]. All the Precursor Ions within the isolation window are 
simultaneously fragmented and a single MS/MS spectrum records the 
product ion peaks. The significant difference here is that, in the DIA 
mode, all the precursors in the isolation window have equal chance to 
get fragmented. This in theory confers full fragmentation coverage for 
every MS1 scan and also enables accurate MS/MS ion chromatogram 
construction and quantification of fragment ions. As MS/MS-level 
quantitative data can be used as repeated measurements of Precursor 
Ions in the statistical analysis, it has been shown that DIA mode data 
paves the way for more sensitive statistical analysis in proteomics 
research [17]. However, analysis of DIA data is limited by the ability to 
deconvolute mixture MS/MS spectra of co-eluting ions, which is highly 
likely to be prevalent in small molecule analysis. Although there are 
some algorithms developed to address this drawback, the informatics 
challenge to de-convolute the resulting MS/MS spectrum is still a major 
bottleneck [18-20].
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1.3. Challenges in the bioinformatics for raw mass spectrometry 
data processing 
Figure 1 shows the current pipeline for untargeted metabolomics, the 
raw MS1 data is first processed by peak detection/deconvolution, cross 
samples RT and m/z alignment and intensity normalization. Then the 
quantitation table with m/z and RT coordinated are exported. Once the 
metabolites are robustly quantified, there are many statistical methods 
to perform the desired analysis. Next, the metabolites of interest are 
identified by both MS1 precursor m/z and MS/MS fragment pattern if 
available. Although there are several tools and algorithms developed 
for each step in the pipeline, there are still limitations yet to be 
addressed.
Figure 1. General workflow of current untargeted metabolomics data 
processing.
1.3.1. MS1 level processing pipeline
In LC-MS setting, metabolite mixtures are first separated by LC, where 
different compounds will elute at different RT intervals according to 
their chemical/physical properties. The eluent is then separated 
















compounds will be represented by their elution profiles at specific RT 
intervals and m/z values, while the RT and m/z values can be used for 
identification and the area/peak apex of the elution profile can be used 
for quantification (Figure 2a). However, in real LC-MS experiment 
where thousands of compounds are analysed together, the data will be 
much more complicated (Figure 2b).  i) The data is alway prone to 
background noise and errors introduced by the instruments or the 
person who did the experiment. ii) In complicated samples (such as 
human sample), it is likely that there exist different compounds of the 
same m/z value and there may be overlap of their elution profiles so 
that the elution profiles cannot be easily deconvoluted. iii) the existence 
of isotope peaks makes the data more noisy. As a result, the first 
challenge is the correctly peak detection of different compounds for 
each sample which includes background noise deduction, elution 
profile deconvolution and isotope peak identification. After the peak 
detection for each sample, the next step is to align the peaks across 
samples, where the peaks are aligned on both RT and m/z dimensions. 
The common approach is to set certain threshold for RT and m/z and 
align the peaks within the threshold across the samples.
Although existing open source software packages such as 
MZmine [21] and XCMS [22] perform peak picking and alignment for 
MS1 data, there is room for considerable improvement [23]. For 
example, missing data is a very common problem in aligned peak data, 
and a large proportion of these cases stems from errors in the signal 
processing steps.  In our observation, even the most sophisticated 
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multi-sample alignment algorithms have been prone to misalignment 
error at the individual compound level, especially for less abundant 
compounds or multiply charged compounds. Misalignment tends to 
happen when 1) signal detection algorithms fail to separate co-eluting 
compounds, 2) peak picking algorithms identify incorrect major isotopic 
peaks, or 3) minor temporal variation that goes beyond the tolerance 
level specified in the alignment step by a few seconds of RT or a few 
decimals in the m/z in those algorithms. 
Figure 2. (a) Ideally, different compounds form clear ion 
chromatograms in LC-MS. However, real data (b) are much more 
complex than expected.
Before the statistical analysis of the aligned data, the peak 
















order to remove the systematic bias introduced during sample 
preparation, the variation in the ionisation efficiency and instrument 
conditions. Common choices for normalising metabolomics MS data 
include total intensity sum (TIS) [24], internal standard calibration (ISC) 
[25], or a statistical model that combines ISC and TIS [26]. However, 
the existing methods for data normalisation also have limitations. For 
example, the internal standard measurements can be inaccurate in 
some samples, or mixed with co-eluting compounds. The TIS method 
may fluctuate due to poor chromatographic separation or the influence 
of a few dominantly abundant compounds, and it can also be 
inapplicable when the detected compounds are genuinely 
heterogeneous between comparison groups. Most importantly, the 
procedures mentioned above are corrections by a single constant, 
which adjusts all intensity values for global bias only and does not 
account for temporal or local variations along the RT axis across 
different samples [27].
1.3.2. Compound identification and MS/MS spectral library
Unlike MS-based proteomics, where the MS1 peptide sequence can be 
predicted by the MS/MS fragment pattern and then aids the 
identification of protein, metabolites cannot be comprehensively 
identified using MS/MS spectra: fragmentation spectra generally 
contain a small number of uniquely representative fragment peaks in 
metabolites, and some peaks do not appear in all instrument setups 
depending on the parameters such as collision energy and ionisation 
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mode. More importantly, the exact fragmentation mechanism is poorly 
understood for small molecules, especially when compounds are 
extracted from complex biological matrices. This variability in MS/MS 
data precludes the option of automated MS/MS-based identification via 
database search, which is often employed in proteomics applications 
where theoretical spectra can be constructed for all proteins (peptides) 
from in silico translation of fully sequenced genomes. 
In the absence of systematic sampling of MS/MS, assignment of 
compound identity relies on monoisotopic mass search of MS1 
Precursor Ion peaks (or peak features) against a reference library such 
as PubChem [28], HMDB [29] and METLIN [30] with desired mass 
accuracy criteria, or isotope-based inference in an open search space 
[19, 31](Figure 1) and/or compare the RT with standard compounds. 
However, if we consider all possible forms of each compound with 
different adduct ions, as they are present in complex biological 
matrices, even a narrow mass tolerance window around a target mass 
value may contain multiple compounds, and this ambiguity cannot be 
resolved by open space search of MS1 data alone. To make matters 
worse, Precursor Ion peaks tend to have a single peak in small 
molecules (without reliable isotopes), in which case charge state 
deconvolution is impossible and therefore single charge is assumed in 
practice.
As a remedy to address the uncertainty, putative compound 
identities can be validated by post-hoc MS/MS validation for selected 
Precursor Ions; experimentally acquired MS/MS spectra are queried 
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against well-known reference MS/MS libraries such as NIST [32], 
MassBank [33], LipidMaps [34] in addition to the others mentioned 
above. Nevertheless, the possibility of resolving unique compound 
identity in this workflow is also dependent on the assumption that the 
existing databases have MS/MS records corresponding to a compound 
and how reproducible the fragmentation pattern is across different 
instrument setups, since reference libraries are generated in a specific 
instrument setup after all.
Besides the public spectral libraries, construction of customized 
spectral library is another promising approach for compound 
identification. In this approach, pure standard compounds are profiled 
in the DDA mode and MS/MS spectral library can be built for a given 
type of biological samples. The advantage of customized spectral 
library is that the fragmentation pattern variation cause by instrument 
setup is minimised. However, the number of identifiable compounds is 
also limited by the availability of pure standard compounds. 
Furthermore, there may be different adduct types in complex biological 
samples and the adduct type difference should also be considered in 
identification step.
1.3.3. MS/MS level analysis in DIA mode
As mentioned in Section 1.2, there are two common methods to obtain 
MS/MS data: DDA and DIA. The main advantage for DIA mode is that 
all detectable precursors in the full MS1 m/z range are fragmented and 
analysed, and the MS/MS fragments can be quantified by ion 
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chromatogram integration as repeated measurements of the 
precursors, a significant departure from conventional DDA analysis. For 
targeted extraction of MS/MS fragment, existing spectral library can be 
used to recover the precursor-fragments link [18]. In this approach, 
customized library extraction has the advantage in extraction accuracy, 
whereas public library extraction has a wider coverage compounds. 
However, as discussed in Section 1.3.2, the lack of comprehensive 
MS/MS spectral library has also limited the potential for library-based 
approach. Therefore, library-free approach seems to be more 
appealing. 
Recently, a few algorithms developed for the library-free 
extraction: DIA-Umpire for proteomics applications [18] and MS-Dial for 
metabolomics applications [19]. DIA-Umpire uses correlation of ion 
chromatograms between the precursors and fragments to construct 
pseudo precursor-fragment links. MS-Dial is a similar type of software 
package for metabolomics data, which uses mathematical 
deconvolution method to recover the precursor-fragment links. 
However, there are still limitations that are not addressed in the two 
methods above. DIA-Umpire uses a probabilistic model to find the most 
likely pseudo precursor-fragments pairs, but the data processing 
pipeline is entirely tailored for proteomics data processing. By contrast, 
MS-Dial was developed for metabolomics but the major limitation is 
that the MS/MS data are not used for quantification of metabolites. In 
addition, using the above two methods, the false discovery rate (FDR) 
of the precursor-fragment pairs cannot be controlled at all: the only way 
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to validate the compound identity is to reference the spectral data 
against an existing spectral library.
1.4. Contributions
As discussed in Section 1.3, there are limitations in MS1-based cross 
sample m/z and RT alignment, data normalisation, metabolite 
identification, MS/MS spectral library construction and DIA-MS data 
processing. In the following two chapters, I will present computational 
approaches to address the limitations mentioned above in the current 
bioinformatics pipeline. In the first method, we developed a software 
package implementing a novel method to address cross-sample peak 
misalignment of MS1 peak data and a retention time-based 
normalization method to correct for systematic bias in chromatography 
across multiple samples, an important parameter of variability in the 
analysis of a large number of clinical samples. In the second method, 
we developed a workflow to build MS/MS spectral libraries for 
metabolites, which are customized for any instrumentation set-up 
within a laboratory, and to perform quantitative analysis using ion 
chromatogram data of product ions. This workflow not only increases 
the chance of precise compound identification, but also allows users to 
accrue mass spectral information over time and improve their ability to 
identify compounds more precisely. More importantly, we show the 
potential of MS/MS data as a source of complementary quantification in 
clinical metabolomics analysis.
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Chapter 2: MetTailor: Dynamic Block Summary and Intensity 
Normalization for Robust Analysis of Mass Spectrometry Data in 
Metabolomics
This paper was published in Bioinformatics 2015 and the R package 
“MetTailor” and the isotopic ratio extraction program are freely available 
at the SourceForge website http://mettailor.sourceforge.net/.
2.1. Introduction
As discussed in the previous chapter, the general workflow for MS data 
preprocessing consists of several steps. First, peak picking algorithms 
are applied to identify the ion chromatograms with robust isotopic 
patterns and each of them is reported as a peak feature with three-
dimensional coordinates (m/z value, retention time, and peak areas/
intensities, often aggregated over isotopes and adducts into a major 
peak feature). Next, the peak alignment step removes the variations in 
both RT and m/z axes for the same compounds across the samples, 
aligning the extracted peaks to the same m/z and RT grid to a single 
identifier. The aligned peak intensity data are then further processed by 
a normalization procedure prior to statistical analysis, however, there 
are still limitations especially in missing values caused by mis-
alignment and the inability of the existing normalization method to 
adjust variations along RT axis. To address these two key limitations in 
the current data processing pipeline, we developed a software package 
MetTailor, which implements two post-extraction processing steps 
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including a method for block-wise quantitative summary and a novel 
normalization procedure.
2.2. APPROACH
2.2.1. Dynamic Block Summary Algorithm
To address misalignment events in large sample data sets, we 
developed an algorithm called Dynamic Block Summary (DBS) that 
takes de-isotoped and pre-aligned peak intensity data reported from 
data extraction software packages and dynamically reduces local 
misalignment errors in the chromatographic space (m/z and RT grids). 
The DBS algorithm creates rectangular blocks with m/z and RT grid 
coordinates that are small enough to capture a single compound in the 
majority or all of the samples, and then acquires quantitative summary 
for each block by the peak apex or the largest integrated peak area for 
downstream analysis in each sample. The resulting quantitative data 
corrects a certain degree of alignment errors when merging a large 
number of samples, yielding fewer missing data in the data table 
reported by blocks.
Figure 3 illustrates how the DBS algorithm works. The data 
shown are the raw peak intensity data from Agilent 6520 Q-TOF 
instrument, prior to any signal extraction in the Dengue data set (see 
Results Section 2.4 below) [25]. In each example, the XCMS [22] tool 
reported at least 2 consecutive rows across the samples for the same 
compound. The point where the horizontal line and the first vertical line 
crosses indicates the alignment coordinate for a particular row in the 
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XCMS table (the two other vertical lines are expected m/z coordinates 
for their isotopes). In all panels, alignment was successful in the first 
three samples at the fixed m/z-RT coordinate (i.e. thus reported in the 
same row in the original table), while it failed in the fourth sample 
despite having a very similar m/z-RT coordinate (horizontal or vertical 
shift in the alignment point). Since the DBS algorithm places 
rectangular blocks, it is able to bring the fourth sample back into the 
correct alignment and to summarise the maximal intensity data inside 
the box across all the samples. As a result, this process merges the 
two rows representing the same compound in different samples into a 
single row.
2.2.2. Isotopic pattern validation
The local realignment achieved by the DBS algorithm does not always 
merge the intensity data of the same compound. We thus propose to 
use the isotopic patterns, represented by the intensity ratios between 
the mono isotopic peak to the next two isotopic peaks, and the charge 
state as the quality metric of alignments. In other words, if the DBS 
algorithm correctly realigns a peak in a sample to a different m/z-RT 
coordinate, then its isotopic pattern and charge state should be 
consistent with the peaks from other samples that had been well 
aligned to the same coordinate. To do this, we provide a program as a 
part of MetTailor distribution to identify peak clusters around fixed m/z-
RT coordinates from the raw MS data and extract their isotopic 
patterns and the charge states.
 16
Figure 3. Raw Q-TOF data prior to preprocessing by XCMS. Each 
circle is a unique peak extracted from the corresponding mzML file, 
whose intensity is indicated by the heat colour (white: low intensity; red: 
high intensity). The green boxes are the blocks placed by the DBS 
algorithm. The case of failed alignment is presented in the fourth 
sample in each row, where the corresponding intensity data in the 
misaligned sample appeared in a separate row for that sample in the 
table reported by XCMS. The three panels show the different 
misalignment scenarios, but the DBS corrects the misalignment error in 
each case.
2.2.3. Retention Time-based Local Normalization
We also propose a novel normalization procedure that does not adjust 
all intensity values by a constant normalization factor. When a large 
number of samples are processed through a GC-MS/LC-MS platform, 
there are numerous temporal factors that can affect intensity 
measurements over the chromatographic time and subsequent steps 
such as the ionisation efficiency in electro-spray ionisation (ESI)-MS 
 17














































































































































platforms. To address this, we developed a RT(δ)-based normalization 
method, in which the normalising factor is acquired by the weighted 
sum of peak area values in the RT neighbourhood (of size δ) of each 
compound at a specific RT.
The algorithm automatically determines the optimal window size 
δ (see methods Section 2.3 for details). In the RT regions where few 
compounds are found, the algorithm recognizes the scarcity of data 
and borrows the information from other RT regions with a sufficient 
amount of data. By design this procedure can adaptively remove 
temporal variations in the intensity data, and it becomes equivalent to 
the TIS normalization in the absence of such local variations. It is also 
advantageous in that it prevents a few intense compounds from 
dominating the normalizing factor across all ions within each sample. 
2.3. METHODS 
The starting material for MetTailor is the aligned data reported by the 
software packages such as MZmine and XCMS. We denote the 
intensity data as Y = { yj } = { yjtm },where the subscripts t = (1,…, T), m 
= (1,…,M) and j = (1,…,n) are the indexes for aligned retention times, 
mass-to-charge ratio (m/z), and samples respectively. Hence yjtm is 
interpreted as the intensity of a peak at the aligned grid of RT rt and m/
z xm in sample j. T and M are the number of unique RT and m/z values 
appearing in the aligned data respectively. We also define the block 
center as the middle of the m/z-RT grid coordinates.
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2.3.1. Dynamic Block Summary (DBS)
Step A Block Initialization: Given the aligned data, the DBS 
algorithm starts by initializing the blocks, where each block is uniformly 
sized covering m0  m/z and r0  seconds in the chromatographic space 
(default values m0 =1.2 and r0 = 6 seconds). For each block, the 
algorithm goes through a series of decision criteria to determine 
whether the current block definition is optimal or not. To explain the 
criteria, we have to define the optimality of peak alignment first: we 
consider the original processing software has aligned a peak well if, 
under the reported alignment, the peak intensity is above a minimal 
intensity threshold I* (default 2,000) in at least p% of the samples 
(default p=80). We say that a peak intensity is missing in a sample if its 
intensity is below I*   or unreported. After initialization of blocks, each 
initial block may contain no well-aligned peak, one such peak, or more 
than one peaks, and the iterative block updates have customized steps 
for block position adjustment or segmentation in each of the three 
cases. 
Step B1 Iterative Updates: One well-aligned peak. If the initial 
block already contains a single well-aligned peak and the block center 
is located on the m/z-RT grid of the peak, then the DBS terminates the 
block update for the current block and moves onto the block summary 
step (Step C). If not, it repositions the block so that the block center is 
at the grid of the well-aligned peak and the algorithm returns to Step A 
to restart the checklist (whether the modified block still contains only 
one well-aligned peak).
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Step B2 Iterative Updates: No well-aligned peak. If the initial 
block contained no well-aligned peak meeting the criteria, then the 
DBS identifies a “lead” peak, defined as the peak with the smallest 
number of missing data across the samples. If there are more than one 
such lead peaks, then the mean m/z-RT coordinate is defined as the 
lead peak. If the current block center coincides with this lead peak, the 
DBS terminates the block update and moves on to the block summary 
step. If not, it updates the grids of the block so that its center is placed 
on the lead peak, and returns to Step A to restart the checklist.
Step B3 Iterative Updates: Multiple well-aligned peaks. If the 
initial block contains two or more well-aligned peaks of different m/z 
and RT grids, then the DBS removes the current block definition, 
creates one block for each of the peaks, keeping the block size the 
same in both m/z and RT axes, and then returns to Step A (recording 
that this duplication move was made). If the DBS returns to this same 
point of multiple peaks situation (D peaks), with a record of duplication 
move, then it breaks the current block into D segments. Each segment 
retains the same m/z range as the parent block, but the RT range will 
now be defined by setting break points at the mid points in the RT axis 
between the D well-aligned peaks. After block segmentation, the 
algorithm returns to Step A. These updates are iterated until there are 
no more blocks containing multiple well-aligned peaks.
Step C Summary of intensities and removal of replicated peaks. 
Once the DBS moves onto this stage for each block, then it 
summarizes the intensity value for the block as the highest intensity 
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value, which corresponds to either the apex of an elution profile or the 
integrated peak area, depending on the initial data processing scheme. 
Finally, the DBS goes through the list of summarized blocks and 
removes duplicated blocks. 
2.3.2. Isotopic Pattern Validation
As a means to extract and compare charge states and isotopic patterns 
of realignments, we also implemented a program to first extract the 
MS1 raw peaks from the m/z-RT coordinates in the aligned data. The 
peak extraction is performed for m/z neighborhood with default 
parameters of -2 amu to +4 amu on the m/z axis and -20 to +40 
seconds in the RT axis. It then routinely determines the charge states 
of the candidate compound and extracts the isotopic peak intensity 
pattern in the form of ratio between the mono isotopic peak and the 
subsequent two isotopic peaks. For each aligned peak, the program 
reports the mean and standard deviation of the isotopic ratios across 
the samples. For a newly recovered peak, we consider the peak is well 
recovered if its isotopic ratio falls within a reasonable range of the 
distribution of the ratios in the samples with good initial alignments (e.g. 
95% percentile). 
2.3.3. RT(δ) normalization
Following the DBS algorithm, MetTailor offers a data normalization 
step, where the user can choose either the TIS normalization or a 
novel method called RT(δ), or opts to skip the normalization step.
 21
2.3.3.1. TIS normalization. 
For the TIS normalization, we first compute sample specific TIS 
and transform the data by
Following this step, we rescale the entire data set so that the 
total normalised intensity across all compounds and samples is equal 
to the total sum of pre-normalization intensities. This step ensures that 
the normalized intensity values are on a comparable scale with the raw 
intensity values.
2.3.3.2 RT(δ) normalization. 
In this new normalization procedure, we transform the data as follows. 
At the block indexed by (t, m), we first compute the sample-specific 
local weighted intensity sum
for all j, where               is the Gaussian kernel function with standard 
deviation δj . We transform the data by
for all peaks (with m/z value xm). Here the “size” of the weighting 
function δj can be provided by the user, or determined by our 
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automated algorithm (see below). Following this correction, we rescale 
the data in a similar way as the TIS normalization, but at a specific RT 
grid. In other words, we rescale the data at each RT grid so that the 
total intensity sum is the same between the raw data and the adjusted 
data at the specific RT. This step ensures that the order of absolute 
abundance levels is roughly retained across the compounds after 
normalization. Note that the window size δ should not be too small 
since the scaling factor will be dominated by the intensity of the 
compound itself, especially in highly abundant compounds. On the 
other hand, larger will draw this algorithm closer to the TIS 
normalization.
Automated selection of { δj }. We search for the optimal δj  for 
each sample as follows. We first transform the data by 
so that the data is scaled to have the same TIS across all the samples. 
We then place a sliding window with size 1 min and slide the window 
by 30 seconds each time, recording the intensity sum in each sample 
at each position of the sliding window. For sample j, we look for the 
sample with the most distinct TIC profile, say k, for which we compute 
the intensity sum differences across all the windows and find the 
longest streak of consecutive windows with an identical sign (positive 
or negative). We iterate the same search for each sample to determine 
the optimal window size, and then set δj as a quarter of the window 
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size, based on the fact that four times the standard deviation  of a 
Gaussian kernel will cover 95% of such a window size.
2.3.4. Model-based significance analysis
For the differential expression analysis of block-summarized and 
normalized data, we used the hierarchical Bayesian model proposed 
by Wei and Li (2007) [35], implemented in the mapDIA software. 
mapDIA was initially developed for quantitative proteomics data 
analysis obtained from data independent acquisition MS (DIA-MS), but 
the differential expression analysis component is directly applicable to 
any intensity data. In the model, two possible probability models of 
intensity data are proposed for each compound, namely differential 
expression (DE) model and non-DE model respectively, and the 
posterior probability of DE is calculated. The posterior probability 
scores are used to select the differentially expressed compounds and 
is used to compute the false discovery rates (FDR) [36].
The implementation of this model is available through the 
SourceForge portal at http://sourceforge.net/projects/mapdia/. In 
mapDIA analyses, we turned off data filtering options only relevant to 
the DIA-MS data.
2.3.4.1. Basic Modelling Framework
The analysis is based on Bayesian latent variable model with Markov 
random eld prior, an adaptation of the model described in Wei and Li 
[35] with application to genomic data analysis. While our 
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implementation automatically performs all pairwise comparisons 
requested by the user, here we illustrate using a comparison for two 
groups of samples for the clarity of explanation. Supposed the data, 
denoted by Y, were median centred, then the probability model can be 
written as
where the observed data yp for compound p is associated with the 
latent state zp. zp = 1 and zp = 0 indicate that compound p is 
differentially expressed (DE) and non-differentially (equally) expressed 
(EE hereafter), respectively. Denoting the two groups in comparison by 
i and j, 
where π(Θz) denotes the prior distribution of all model parameters for 
DE status z. Here Ψ(-) denotes the product of all element-wise 
Gaussian densities, i.e.
where                              and                          in compound p.  Note that 
the variance parameter        is set separately estimated for the two 
models. The priors and closed form expression of                        for DE 
and EE is omitted here. 
 25
2.3.4.2. Markov random field (MRF) model, significance scores 
and false discovery rates (FDR)
We denote the true (unknown) state by Z* and interpret this as a 
particular realization of the random vector Z. Our goal is to recover the 
true state Z* from the observed data Y across all comparisons,
where the joint distribution of Z is approximated by the Markov random 
eld (MRF) model (equation 2)  
with      denoting the set of neighbour compounds of compound p. Note 
that, if the module information is not utilized (β = 0), then the entire 
model will be equivalent to the mixture model treating the latent states 
as independent binary random variables. From the model above, we 
can derive the overall optimal solution Z* or derive the posterior 
probability of DE (with no module information) as the significance score 
for comparing group i and j:
Here                  represents the prior probability of differential 
expression in the dataset, i.e. the estimate proportion of DE 
compounds. In addition, we provide the posterior odds
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as a supplementary score (in natural log scale), which is useful when 
further prioritization is needed among the high scoring compounds (e.g. 
among the compounds scoring       = 1).
When the module information is utilized, the probability and 
odds scores are derived in the same manner by using the 
approximation
Once the scores       are computed (omitting groups in the notation), 
the Bayesian FDR [36] is computed as 
2.4. RESULTS
2.4.1. Data sets
We used two published data sets to evaluate the performance of 
MetTailor in this work. The first is the metabolomics data set of 24 
samples with extracted feature map (featureXML files) and curated 
alignment from Lange et al. (2008) [37]. We will call this data set M2 
data following the reference in the original paper. Following the steps in 
the paper, we also made the XCMS read the featureXML files skipping 
its peak detection step, and perform alignment and retention time 
correction with the same parameters as reported in the paper. For 
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MetTailor, we used all default parameters other than setting the minimal 
intensity 0 to avoid removal of any data points. Then we benchmarked 
all DBS-recovered peaks to the curated peak alignment for verification.
The second data set is from a recently published metabolomics 
study for Dengue virus infection (Cui et al., 2013) [25] (Dengue data 
hereafter). The goal of this study was to identify differentially expressed 
metabolites in the sera samples of Dengue patients at different phase 
of infection and recovery. In the study, blood samples were taken from 
49 control subjects and 27 subjects diagnosed with acute Dengue fever 
(DF) but not life threatening Dengue haemorrhagic fever/Dengue shock 
syndrome, where samples were collected from the patients multiple 
times at early febrile (rising fever), defervescense (abating fever), and 
convulscent (recovery) stages. This comprises 115 MS runs in total. 
The samples were analyzed using Agilent 6520 Q-TOF mass 
spectrometer coupled with UPLC.
We processed the data using XCMS [22] to perform peak 
detection and alignment, and applied MetTailor to the output data. In 
the XCMS processing, the following default options were used.
• Step 1: Run peak nding in batch mode with the default setting 
xset = xcmsSet(inputfiles,nSlaves=4)
• Step 2: Apply "obiwarp" method to correct retention time deviations
xset1 = retcor(xset, method = “obiwarp")
• Step 3: Align peaks across the samples using overlapping m/z bins 
and calculation of smoothed peak distributions in chromatographic 
time. The bandwidth of gaussian smoothing kernel to apply to the 
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peak density chromatogram was set at 5, and the minimum fraction 
of samples necessary in at least one of the sample groups for it to 
be a valid group to be 0, so that the program reports any peaks with 
at least one sample (to prepare our starting material).
xset2 = group(xset1, bw = 5, minfrac = 0)
• Step 4: Export the aligned peak table.
peakTable(xset2, filebase="peakList1")
For MetTailor processing of this data, we set default parameters. 
For quality assessment of realigned peaks, charge states and isotopic 
peaks intensity patterns were extracted from the raw data using the m/
z-RT coordinates reported by MetTailor. RT(δ) normalization was 
performed with the automatically optimized window size . For the 
statistical significance analysis using mapDIA, we set the score 
thresholds associated with 5% FDR.
2.4.2. DBS algorithm
2.4.2.1. The DBS algorithm recovers misalignments with high 
sensitivity and specificity. 
The M2 data contains on average 16122 features in the 24 samples 
and the authors have curated 2630 gold standard peaks by consensus 
peak groups with annotations from the CAMERA package [38]. As 
reported in the reference paper, the initial alignment by XCMS [22] had 
recall rate 98% and precision 78%. However, MetTailor discovered a 
small proportion of misalignment events (21 misalignments within 8 
unique m/z-RT coordinate) and 19 recoveries of these 21 were 
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consistent with the curated alignment. Hence, through MetTailor, we 
verified that XCMS achieved the initial alignment really well for the 
majority of the gold standard peaks and a small number of misaligned 
cases were re-aligned. We note that, however, the curated peaks 
comprise merely 16% of the entire peak list and these high quality 
peaks with consistent annotation are expected to be aligned well, and 
therefore our evaluation based on this data set is quite limited.
In the Dengue data, the table initially reported by XCMS 
contained 7920 aligned peaks appearing in at least one of the 115 
samples. Similar to the M2 data, many peaks were localized to highly 
consistent m/z and RT coordinates across the samples, if not perfectly 
aligned across the samples. In the reported table, misaligned peaks 
appeared as different peaks, and if the intensity levels are compared 
between groups of samples (DF stages), then the samples with 
misalignments will be considered as missing data, affecting the 
statistical analysis. The DBS algorithm alleviated this burden 
considerably by merging these misaligned peaks into single blocks, 
while decreasing the frequency of missing data at the same time. 
Specifically, the DBS algorithm reduced the number of aligned peaks 
from 7920 to 6915. In this process, the algorithm corrected total of 
6989 misalignments, accounting for 2.2% of 315454 non-missing data 
points in the final data. To verify that the realignments by the DBS 
algorithm are likely recoveries into the correct line of the table, we 
compared the isotopic patterns of the recovered peaks to those of 
samples with good initial alignment. We could extract clear isotopic 
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patterns from 2380 recovered peaks at 285 unique m/z-RT coordinate, 
and the isotopic ratios between the first and second isotopic peaks fell 
in 95% of the ratio distributions from the previously well aligned peaks 
in 1938/2380 of the cases (81.4%). Combined with the similarity of m/z-
RT coordinates, this reflects high quality realignments by the DBS 
algorithm across the data set.
2.4.2.2. Misalignments arise from a few major sources
The fact that merely 2.2% of the peaks were corrected confirms that 
the initial data extraction and alignment was of a high quality in this 
data. To gain insights for the source of misalignments, we plotted the 
distances to the misaligned peaks on both m/z and RT axis from the m/
z-RT coordinate to which the majority of the samples are aligned 
(Figure 4). 4601/6989 misaligned peaks showed m/z shift of 0.4-0.6 
amu and 681/6989 misaligned peaks showed a m/z shift by 0.27-0.4. 
This suggests that these compounds are likely doubly or triply charged 
and the misalignment was caused by incorrect grouping of the isotopic 
peaks. This occurred frequently in the data when multiple co-eluting 
compounds in the vicinity of m/z-RT regions, since the elution profiles 
of the isotopic peaks overlap. Misalignment also happened when minor 
temporal variations outlast the alignment step by a few seconds of RT 
or a few decimals in the m/z beyond the tolerance level specified in 
those algorithms.
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Figure 4. The RT and m/z differences of misaligned peaks to the m/z-
RT coordinate to which the majority of the samples aligned in Dengue 
data. The dashed lines were drawn at     1/2 and     1/3, which indicates 
that misaligned peaks are likely from doubly or triply charged 
compounds. 
2.4.2.3. Block-wise recovery reduces missing data in RT regions 
with active chromatographic elution. 
To better understand the benefit of the DBS algorithm, we further 
investigated where in the chromatographic space (RT and m/z) and in 
what abundance range the DBS algorithm recovered misalignments. 
Figure 5 shows the number of recovered misalignment events across 
115 samples in the Dengue data, in terms of the chromatographic time 
(RT) and the abundance range. Figure 5A shows that the frequency of 
re-alignments by the DBS algorithm is correlated with the cross-sample 
TICs (dashed line), which was computed as the sum of TICs across the 
RTs. At the same time, Figure 5B shows that misalignments occurred 
mostly for low to medium intensity peaks. Taken together, this suggests 
that the misalignment occurs more frequently for low abundance 
compounds in active RT regions with elution of multiple compounds. 
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This also indicates that the alignment procedure built in XCMS is 
primarily driven by the most intense peaks in local RT regions.
Figure 5. The frequency of missing data recovery by the DBS 
algorithm in the Dengue data (115 runs) across the RT (A) and the 
abundance range (B). The dashed line is the cross-sample local sums 
of TICs in sliding windows of RT (after scaling to the misalignment 
frequency plot).
2.4.3. Normalization
Next we tested three different normalization methods, including the 
internal standard calibration, TIS normalization, and RT(δ) 
normalization. Note that the first two normalization methods uses a 
single constant as the normalizing factor for each sample, while the 
RT(δ) adjusts the normalizing factor locally at each RT grid in each 
sample. The first two methods are also different from each other in the 
sense that the first uses a known compound added to sample when 
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preparing for LC-MS whereas the TIS is calculated from the extracted 
intensity data.
Figure 6. TIC plots across random selected 14 samples in the Dengue 
data with (A) no normalization (DBS), (B) total intensity sum (TIS), (C) 
internal standard calibration (ISC), and (D) retention time (RT) 
respectively. Purple and orange lines are the pair of two samples with 
the lowest correlation.
Before we compared the normalization methods, we first 
examined the raw data and discovered that there was no visible 
variation in terms of the total ion chromatogram (TIC) profiles across 
the samples, indicating that there was no constant systematic variation 
in the chromatography across a large number of MS runs (mean 
correlation 0.971 and 95% confidence interval (0.925,0.994)). However, 
a closer examination revealed temporal variations in TIC across many 
samples. Figure 6A shows the TIC plots in the raw intensity data, with 
a pair of samples highlighted in purple and orange colors. It is easy to 
see that the sample in pink had much higher intensities between 600 
and 800 seconds, while the pattern dissipated after 800 seconds. Even 
though these two samples were from different patients, the overall total 
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intensity differences were very specific to certain RT periods and this 
pattern was consistently observed across many pairs of samples.
2.4.3.1. Internal standard calibration and TIS normalization
The acetic acid standard (9-fluorenylmethoxycarbonyl-glycine) showed 
little variation across the samples in the Dengue data (Figure 7). The 
internal standard appeared in the middle of the RT range (408 second) 
and their intensities were not dominant (the standards accounted for 
0.3% of the TIS). Meanwhile, the TIS values were also calculated for 
normalization. Interestingly, the TIS values were not correlated with the 
intensity values of the internal standard (Pearson correlation 0.11; 
Figure 7). As a result, the normalized data were substantially different 
between the two methods (Figures 6B, 6C) and this also led to unique 
sets of compound selected in the DE analysis (see below).
Figure 7. The scatter plot of the acetic acid internal standard (9-
glycine) and the total intensity sum (TIS) used for ISC and TIS 
normalization for the Dengue data. The two normalization factors are 
clearly not correlated overall. The positive slope of the regression lines 
is due to the three outlier samples drawn in the lower left corner of the 
plot.
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2.4.3.2. RT(δ) normalization removes temporal variation along the 
RT axis. 
For the RT normalization,  values chosen by the automated search 
varied in the range of 2-4 minutes, which is around 10% of the total RT. 
Figure 6A suggests that there is a strong evidence of temporal 
variation in the raw data between 400 and 800 seconds. The two single 
constant-based normalization (TIS and ISC) reduced this temporal 
variation at the expense of amplifying the variation in the 800-1,000 
second period across the samples. By contrast, the proposed RT(δ) 
normalization have substantially reduced such variations localized to 
specific RT periods (Figure 6D). In the RT regions with few detected 
peaks, stable normalizing factors could not be calculated and were 
possibly dominated by the compound itself due to the lack of a 
sufficient number of background. In these regions, our procedure 
borrowed information from the median pattern of local intensity sums 
from other RT regions and normalized the data against those values.
2.4.3.3. RT(δ) normalization does not lead to loss of statistical 
power. 
Although we demonstrated that the normalization procedure removed 
local chromatographic variations in the visual sense, it is important to 
verify that this correction neither removes real biological variations nor 
introduces false positives. To evaluate the possibility of such 
consequences, we first performed DE analysis between controls and 
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patients in the febrile stage with normalization options. For the DE 
analysis, we set the significance score threshold to control the 
Bayesian FDR at 5%. We also considered the peaks or blocks that can 
be assigned at least one compound identifier assigned through the 
online HMDB search (tolerance 10 ppm, singly doubly or triply charged, 
[M+H]+, [M+2H]2+ and [M+3H]3+, no other adducts, peptides excluded).
The three normalization methods reported 476 DE compounds 
(significant in at least one method) and 62% were shared by all 
methods. Each method reported a handful of unique compounds 
nonetheless. In RT(δ) normalized data, which we deem to be the 
optimal normalization method in this data, led to a selection of unique 
DE compounds which were more spatially randomly distributed across 
the RT. Moreover, when compounds show DE in both TIS and ISC 
normalized data, a majority of them are also DE in RT(δ) normalized 
data. On the other hand, many of the compounds significant in the TIS 
and RT-normalized data were found to be nonsignificant in the ISC 
normalized data. Figures 8 and 9 show the distribution of significant 
compounds in the data with each normalization method and the 
differences between the three outputs respectively. The latter figure 
verifies that the RT normalization did not lead to potential loss of 
statistical power compared to the other two normalization methods.
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Figure 8. The differences in the DE compounds due to normalization 
methods in the m/z - RT space. Gray circles are the compounds 
significantly DE with at least one of the three normalization methods. 
Red, blue and green circles are the compounds uniquely significant 
(non-significant in the other two methods) (A) and uniquely non-
significant (significant in the other two methods) (B) with each 
normalization method, respectively.
Figure 9. The distribution of the DE compounds (5% FDR) in the m/z 
and RT space for each of the three normalization method. Gray circles 
are the compounds that were found to be significant in at least one of 
the three analyses.
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2.5. DISCUSSION AND CONCLUSION
In this work, we developed a software package MetTailor, featuring a 
novel block summary method called DBS algorithm and an adaptive 
normalization method to remove temporal variations across a large 
number of untargeted MS experiments. These additional data 
processing steps were introduced as a complementary tool for quality 
assurance of the data reported by the extraction tools such as MZmine 
and XCMS. With inexpensive computational effort, these steps can 
address missing data problem and remove local variations that vary 
across retention time in a long series of MS experiments. We also 
provide implementations to extract the charge state and isotopic 
profiles from the raw data at specific m/z-RT coordinates so that the 
users can evaluate the quality of post-alignment peak summary tables 
as a validation step.
2.5.1. Utility of the DBS algorithm
Although the number of re-alignment events was relatively modest in 
our demonstration with both data sets, the DBS algorithm is 
computationally inexpensive and a few minutes of runtime can provide 
an important quality check for the initial alignment data, with additional 
recovery of thousands of misaligned peaks across the samples. We 
expect that the DBS algorithm will be equally useful for data sets 
generated with older generation mass spectrometers (e.g. linear 
quadrupole ion trap MS, old generation Q-TOF) and the next 
generation ones (e.g. Quadrupole-Orbitrap, QqTOF), since the 
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alignment accuracy has more to do with temporal variations in the 
elution rate of individual compounds across the samples, rather than 
the mass accuracy and resolution of MS. A complementary tools such 
as MetTailor will therefore be of great importance from the data quality 
control perspective.
However, we remark that the DBS algorithm is inherently limited 
by the fact that its working material is the preprocessed data, which is a 
significantly compressed form of information for each peak feature as 
centroiding, deisotoping, and compression of adducts is applied during 
the first-round processing. With the ever increasing computation power, 
a more advanced alignment algorithm with a local alignment procedure 
matching individual peak features can be developed, directly utilizing 
various raw peak features such as isotopic distributions and adduct 
information without a severe data compression step.
2.5.2. Missing data imputation
Another important point of discussion is on the use of machine learning 
methods to impute missing data [39]. One may argue that the DBS 
procedure can be replaced by using other imputation procedures such 
as k-nearest neighbour or random forest imputation [40, 41]. To put the 
utility of the two approaches in perspective, it is important to recognize 
the difference in the source of missing data addressed by each 
method. The DBS algorithm is addressing the problem of misalignment 
or variation in the elution profiles of the same analytes across different 
GC-MS/LCMS experiments. Since this approach addresses the 
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missing data problem incurred during the data tabulation process, it 
only deals with the source of missing data that can be corrected within 
the limit of detection of mass spectrometers. 
By contrast, the aforementioned methods perform imputation by 
inference, which do not differentiate between different sources of 
missing data and primarily aim to fill in the missing values based on the 
pattern matching with other compounds. In practice, this group of 
methods should be used carefully in highly variable systems as GC-
MS/LC-MS, as a last resort after all available remedies to correct the 
errors in the data extraction stage have been exhausted. This is 
because the algorithms depend heavily on the availability of informative 
neighbour compounds in the same data set. Moreover, although these 
methods are widely used at present, they were evaluated primarily on 
gene expression microarrays that quantify predetermined molecular 
targets. Hence whether the same procedures will be applicable and 
equally efficient on MS-based metabolomics data sets, plagued by the 
ambiguity of isomers in small molecules, remains to be evaluated.
2.5.3. Data normalization
Finally, we have also proposed a novel normalization algorithm that 
removes temporally systematic variations frequently observed in the 
GC-MS and LC-MS pipeline. Retention time is clearly one of the most 
important anchors of experimental variations in the GC-MS and LC-MS 
platforms [27], which is often ignored in conventional computational 
normalization strategies. It is also important to note that some of the 
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distribution equalizing methods such as IQR-based normalization or 
quantile normalization can introduce over-adjustments, since these 
procedures are applicable only when a certain assumptions are met. 
For example, the procedure based on mean centering and standard 
deviation scaling requires that the overall log-intensity distribution be 
normally distributed. The quantile normalization is not applicable when 
missing data are prevalent and can be risky when there are only a 
handful of metabolites (e.g. a few hundreds) since the procedure can 
easily over-correct intensities of very high or very low abundance 
compounds due to the granularity of percentile points.
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Chapter 3: Customized consensus spectral library building for 
untargeted quantitative metabolomics analysis using data 
independent acquisition mass spectrometry and MetaboDIA 
workflow
This paper is accepted by Analytical Chemistry and The R package 
“MetaboDIA”  is freely available at the SourceForge http://
metabodia.sourceforge.net/ 
3.1. Introduction
As discussed in the introduction chapter 1, metabolite identification 
step is still a bottleneck for metabolomics studies and there are 
limitations for both MS1 and MS/MS based metabolite identification. 
Computational tools equipped with a standardized scoring metric and 
quality control steps for in-house MS/MS spectral library construction 
form untargeted MS/MS data are largely missing in the metabolomics 
literature. Given the rising role of metabolomics in translational 
medicine [42-44], developing a reliable method for metabolite 
identification and spectral library construction is of utmost importance 
in this field. 
In recent years DIA-MS based metabolomics is receiving more 
attention. The general computational pipeline of spectral de-
convolution in DIA-MS relies on spectral assay libraries, and these 
libraries are often acquired from DDA-MS. In metabolomics, however, 
even the availability of DDA data does not produce a clear path to 
robust spectral libraries immediately. This is because it is generally 
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difficult to construct a universally applicable MS/MS spectral library that 
will be reproduced under all experimental conditions, sample types, 
and instrument set-ups. Moreover, there are few computational tools 
tailored for DIA-MS in metabolomics. To the best of our knowledge, 
MS-DIAL[19] and MetDIA[20] are the only tool that can systematically 
identify metabolites based on fragment ions in DIA-MS data. However, 
MS-DIAL utilizes MS/MS data for compound identification using 
existing spectral libraries and does not perform quantification with MS/
MS data. MetDIA performs targeted extraction using XICs of fragment 
ions through an approach termed “metabolite-centric” by the 
developers, but it also requires a spectral library and does not directly 
deal with the construction of reproducible spectral library in a given 
instrumentation set up.  
In this chapter, I will describe an alternative bioinformatics 
workflow called MetaboDIA to construct customized MS1- and MS/MS-
based spectral libraries in the context of large-sample analysis. In 
MetaboDIA, we aim to enable each laboratory to build MS1 and MS/
MS libraries from their own data sets, with a benchmarking capability 
against reference libraries using standardized scoring metric. In this 
platform, users are allowed to retain peak data with putative compound 
identity from past experiments as part of a growing knowledge base in 
the laboratory, instead of discarding the data because the same 
fragmentation pattern had not been observed in external reference 
libraries. In addition, having observed successful targeted extraction in 
samples of high complexity (e.g. ~200 detectable compounds) in the 
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recent literature [20], we set out to test the possibility of using peak 
area or intensity (apex height) values for the fragment ions as a 
complementary method for quantification of metabolites in highly 
complex samples (e.g. serum samples from patients). 
In this work, we implemented this data processing pipeline into 
an R package called MetaboDIA. Using this tool, we first evaluated the 
quality of MS/MS-based relative quantification in triplicate SWATH-MS 
runs of 10 marine algae species and 9 quality control runs in 
comparison with MS-DIAL’s MS1-based quantification. We next 
analyzed human serum samples from 40 age-related macular 
degeneration patients and 20 healthy controls from an age-related 
macular degeneration study, the complexity of which is far beyond the 
samples reported in the DIA-MS literature for metabolomics. Through 
these examples, we show that MetaboDIA provides an efficient 
interface to build customized spectral libraries that can maximally 
utilize MS/MS data as a complementary quantification method for 
metabolites. 
3.2. Experimental Section
3.2.1. Samples and reagent preparation for the AMD data. 
Serum samples were collected from 60 subjects attending the vitreo-
retina clinic at the Singapore National Eye Centre. Age and gender-
matched control samples were selected from banked samples 
collected from participants of the Singapore Chinese Cohort Study [45] 
(see Table 1 below). Detailed sample selection criteria can be found in 
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the Section 3.2.2 below. The study was approved by the SingHealth 
Institutional Review Board and conducted in accordance with the 
Declaration of Helsinki. Written informed consent was obtained from all 
participants. 
800 µL of methanol and 20 µL of d5-tryptophan (5 µM in 
methanol, as internal standard) were added to 200 µL of each serum 
sample. Samples were mixed for 15 min at 25°C and centrifuged for 12 
min at 16,000 g (4°C). The supernatants were divided into two aliquots 
of 410 µL each (separate vials for each ionization mode) and were 
dried in a vacuum concentrator. A quality control (QC) pool was 
obtained by pooling 25 µL from each serum sample. QC aliquots were 
extracted in the same manner.
3.2.2. Study sample selection criteria. 
The data for this study was taken from a prospective, observational 
cohort study involving patients with exudative Age-Related Macular 
Degeneration (AMD) in the Asian AMD Phenotyping Study. Detailed 
methodology has been published in Cheung CM et al [46]. The study 
was approved by the Centralized Institutional Review Board (CIRB) of 
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Table 1. Subject information for the AMD data set.
Groups Age (Mean ± SD) Gender
Control (n =20) 73.2 ± 5.2 10 Male, 10 Female
CNV (n =20) 74.2 ± 4.6 10 Male, 10 Female
PCV (n =20) 73.0 ± 3.9 10 Male, 10 Female
SingHealth, Singapore (protocol number R697/47/2009) and conducted 
in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from each participant. 
At baseline, all patients underwent an interview and 
comprehensive ocular examination including best corrected visual 
acuity testing using logarithm of the minimal angle of resolution 
(logMAR), refraction, slit-lamp biomicroscopy examination, and imaging 
according to standardized protocol, which included color fundus 
photography and angiography with fluorescein and Indocyanine Green 
(TRC-50X/ IMAGEnet 2000; Topcon, Tokyo, Japan or Spectralis; 
Heidelberg Engineering, Heidelberg, Germany). Information including 
medical history and smoking was obtained using standardized 
questionnaire.
Patients were classified as typical AMD and Polypoidal 
Choriodal Vasculopathy (PCV) based on fundus fluorescein angiogram 
and Indocyanine Green (ICG) angiogram. The typical AMD is graded 
based on the modification from the Macular Photocoagulation Study. 
Presence or absence of Choroidal Neovascularization (CNV) is graded. 
On the other hand, PCV is diagnosed if there is presence of at least 1 
of the following criteria: protruded orange-red elevated lesions 
observed by fundus examination; characteristic polypoidal lesions seen 
in ICG. To study the differences in choroidal traits between AMD and 
PCV subtypes, patients with PCV were further categorized on the basis 
of CT into thick (CT >250 µm, n=40) and thin (CT <250 µm, n=38) PCV 
subgroups.
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3.2.3. LC-MS/MS analysis. 
Analysis was performed on an Eskigent UPLC system (AB Sciex, 
Concord, Canada) coupled to a hybrid Q-TOF mass spectrometer 
(TripleTOF 5600+, AB Sciex). Each sample was reconstituted in 60 µL 
of 95/5 water:methanol and 10 µL was injected for each analysis in the 
positive and negative ionization mode, with both IDA and SWATH 
acquisitions. Samples were injected in a randomized order and a QC 
sample was injected after every 10 samples.
3.2.3.1. Reverse phase (RP) liquid chromatography and positive 
ionization mode. 
The column used for analysis in the positive ionization mode was a 
Waters T3 C18 2.1 × 100 mm, 3 μm analytical column (Waters Corp., 
Milford, MA). The mobile phase was 0.1% formic acid in water (eluent 
A) and 0.1% formic acid in acetonitrile (eluent B). The gradient profile 
was 2% B from 0 to 1.5 min, 20% B at 7.5 min, 50% B at 12 min, 95% 
B from 16 to 18 min and 2% B at 19 to 25 min. The column oven 
temperature was 40°C. The source voltages were 5.5 kV.
3.2.3.2. Reverse phase (RP) liquid chromatography and negative 
ionization mode. 
The column used for analysis in the negative ionization mode was a 
Waters XBridge BEH C18 2.1 × 100 mm, 3.5 μm analytical column 
(Waters Corp.) The mobile phase was 5 mM ammonium bicarbonate in 
water (eluent A) and 5 mM ammonium bicarbonate in 95:5 
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acetonitrile:water (eluent B). The gradient profile was 2% B from 0 to 2 
min, 50% B at 11 min, 100% B from 16 to 18 min and 2%B at 19 to 25 
min. The column oven temperature was 45°C. The flow rate was 0.35 
mL/min for both chromatographic methods. The source voltages were 
4.5 kV.
3.2.3.3. DDA acquisition. 
Each IDA duty cycle contained one TOF MS survey scan (180 ms) 
followed by 20 MS/MS scans (40 ms each). The mass range of TOF 
MS and MS/MS scans were 100 to 1000 and 30 to 1000 m/z 
respectively. The following IDA parameters were applied: dynamic 
background subtraction, charge monitoring to exclude multiply charged 
ions and isotopes, and dynamic exclusion of former target ions for 3 s. 
Ramped collision energies of 20 to 40V and -20 to -40V were applied 
for the positive and negative MS/MS scans respectively. 
3.2.3.4. DIA acquisition. 
Each SWATH duty cycle contained one TOF MS survey scan (150 ms) 
followed by 36 SWATH scans (20 ms each). The product ion window 
for SWATH was from 100 to 1000 m/z in steps of ~25 Da. The mass 
range of TOF MS and SWATH scans were 100 to 1000 and 30 to 1000 
m/z respectively. Ramped collision energies of 20 to 40V and -20 to 
-40V were applied for the positive and negative MS/MS SWATH scans 
respectively.
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3.2.4. Data preparation. 
The current implementation of MetaboDIA relies on mature signal 
extraction modules in existing software packages. First, we use 
XCMS[22] and CAMERA[38] for detecting MS1 peak features (isotope 
clusters) in the MS1 data. Second, we use DIA-Umpire[18] extraction 
module to pair Precursor Ions and their fragment ions within each 
isolation window and to quantify MS/MS fragments by peak heights. 
We are also developing in-house algorithm to do these tasks, which will 
be shared in the future releases of MetaboDIA and is not presented in 
this paper.  
3.2.4.1. MS1 peak feature identification and charge state 
deconvolution. 
We used the centwave algorithm in XCMS to extract the XICs of 
Precursor Ions with suggested instrument specific parameters[47]. 
Then we performed isotope peak annotation with charge deconvolution 
in each sample using the CAMERA package[38]. We indexed isotope 
peak clusters by monoisotopic peaks and charge states. The charge 
state can be inferred for some, but not all, precursor peaks without 
isotopes if the MS/MS spectrum is available (as described below in 
section 3.2.4.2). The peaks without a charge state were retained only 
if it was aligned by retention time (RT) with peaks with inferred charge 
state in some other samples.
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3.2.4.2. Linking fragment ion peaks to their precursor. 
We then queried all precursor m/z and RT values of the MS/MS 
spectrum against the peak features from XCMS/CAMERA, which links 
fragment ions to the precursors in each sample. The search criteria 
were mass error tolerance of 30 ppm (user defined parameter) and RTs 
of fragment peaks appearing within the XIC start and end times of the 
precursor. If the linked precursor did not have a charge state assigned 
by isotopes, the charge state is inferred by comparing the largest 
fragment in MS/MS spectrum with the precursor’s m/z value. If m/z 
values of all fragment ions were smaller, then the compound is 
assumed to be singly charged. We sequentially increase charge state 
until all fragment ion m/z values are smaller than the charge corrected 
Precursor Ion m/z. 
3.2.4.3. Construction of molecular formula database and 
assignment of putative formula(e) to MS1 peak clusters (for library 
construction). 
We compiled a database of 13397 molecular formulae with 
monoisotopic mass values for all compounds available in the 
HMDB[29] and LipidMaps[48] databases. Note that not all formulae 
have MS/MS records in the reference libraries. 
3.2.4.4. Extraction of fragment intensity data with DIA-Umpire. 
DIA-Umpire is a unique software package for library-free DIA-MS data 
extraction[18]. The software constructs internal spectral assay library 
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directly from DIA-MS data (with the capability of using external 
libraries) and extracts quantitative MS/MS data in the proteomics 
context. We used DIA-Umpire’s signal extraction module (version 
1.284) with a parameter setting tuned for metabolomics (see Appendix 
1). In the extraction results, we used the Q1 (>2 isotopes in precursor) 
and Q2 (2 isotopic peaks in precursor) output only, discarding the Q3 
output (without precursor peaks). Throughout the manuscript, we do 
not utilize MS/MS peaks that cannot be associated with XIC of a 
Precursor Ion, which can possibly be recovered by targeted extraction 
approaches such as MetDIA[20]. 
Figure 10. MetaboDIA has two workflows. In the default 
pipeline, a consensus MS/MS spectral library is built using DDA 
data (left) and quantification of MS/MS fragments is performed 
using DIA data. Alternatively, the library can be directly 
constructed from the DIA data (r ight). The current 
implementation relies on mature signal extraction software 
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3.2.5. The default MetaboDIA pipeline: DDA library construction 
and extraction of DIA. 
Our default pipeline runs through the steps designed for DDA-based 
library building (left side of Figure 10) and quantification of fragments 
in DIA data. 
3.2.5.1. Spectral library construction. 
Using the output from above, MetaboDIA aligns peak features sharing 
the same molecular formula in the same charge state at specific RT 
across the samples (see MS1 peak feature alignment for more details), 
which we call compound identification units (CIUs). Each CIU contains 
MS1- and MS/MS-level information as shown in Figure 11. MS1-level 
information is stored as a peak cluster containing m/z values of 
isotopes, inferred charge state, and all putative molecular formulae 
whose monoisotopic mass falls within mass tolerance window (30 ppm) 
around a neutral mass value represented by the first isotope of the 
peak cluster. Here we considered various adduct ions including M+H, 
M+2H, M+3H, M+K, M+Na, M+2Na, M+3Na, M+H+Na, M+NH4, 
M+H+NH4 for positive ion mode data; M-H, M-2H, M-3H, M-H-H2O, 
M+Na-2H, M+Cl, M+K-2H for negative ion mode data. Other less 
frequent adducts in electrospray ionization such as dimers/trimers are 
also available as optional features in the software, but we did not use 
them in this work. MS/MS-level information contains the consensus 
MS/MS spectra obtained from all samples. We note that some CIUs 
are duplicates of the same unique compounds at this stage, especially 
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if the XIC exceeds our RT alignment criteria (6 seconds). Another 
possibility is that they are isobaric compounds with the same molecular 
formula.
Next, MetaboDIA examines cross-sample consistency of 
precursor-fragment pairing and reproducibility of fragment peaks 
recorded for each CIU to eventually build a consensus library entry. To 
ensure the mass accuracy of fragment ion peaks in the consensus 
spectrum, each peak is aligned with mass error tolerance of 40 ppm 
(user defined parameter) across the samples, and reproducibility 
criterion across the samples with MS/MS spectrum (e.g. 50%) is 
imposed for each fragment ion (user defined parameter). We also 
required that the resulting library MS/MS spectrum score on average 
0.5 or higher against all MS/MS spectra in individual samples (user 
defined parameter, see below for scoring method). To associate each 
selected peak with a relative intensity value (0 to 1 scale), average 
relative intensity and median m/z value are recorded for each fragment 
ion. 
Finally, fragment ions with low average relative intensities are 
removed in each spectrum (<0.01). To utilize this library for data 
extraction, MetaboDIA exports the library in a flat file format (.txt), 
including putative formulae, charge state, RT, the number of samples 
having a MS/MS spectrum associated with the precursor, the number 
of MS1 peak features with isotopes in the formula identification step, 
and the consensus MS/MS spectrum for each CIU.
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Figure 11. (a) A CIU representing L-arginine in the spectral library 
assembled using DDA data. Putative formulae are assigned by 
monoisotopic mass search of MS1 data against the reference library, 
with the number of samples with RT-aligned MS1 peak cluster. 
Validation section reports the query result (molecular formula and 
compound name) against the reference MS/MS library along with 
spectral similarity score. (b) The MS/MS spectra in the consensus MS/
MS library from the data and the best matching record in MassBank 
database.
3.2.5.2. Fragment ion quantification. 
To prepare for the library-based quantitative data extraction step, 
MetaboDIA performs monoisotopic mass search of MS1 peak features 
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against 13397 molecular formulae and groups the precursor with 
fragments in the DIA samples. With the DDA-based library and 
precursor-fragment groups from the DIA data, the apex height 
(intensity) value of the XIC is extracted for each fragment ion in the DIA 
data (DIA-umpire output). We deliberately use the apex height instead 
of peak area to prevent poor quantification for compounds with a short 
XIC. To link up this data with CIUs in the DDA-based library, 
MetaboDIA searches for the molecular formula and charge state across 
MS1 peak features in the DIA samples for each CIU in the library, and 
identifies the peak features within the RT range (±60 seconds from the 
RT in the library entry, user defined). Finally, it selects the peak feature 
with the highest MS/MS spectral similarity score (see scoring explained 
below) and extracts fragment ion intensity values from a matching peak 
in the library spectrum with mass error tolerance of 40 ppm (user 
defined option). This process occurs iteratively in each sample, and the 
MS/MS quantification results are merged and reported into a tab-
delimited file (.txt). We remark that this is not the same as fully targeted 
extraction solely based on MS/MS data. In this work, we only used the 
MS/MS data clearly associated with a MS1 peak feature. Therefore, 
while our quantitative data consists of fragments of high precursor 
specificity, the current pipeline results in missing values in samples with 
unclear precursor-fragment mapping, which we discuss later.
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3.2.6. Alternative DDA-free Pipeline (DIA-based library). 
In the case where DDA data are not available, the user can also build 
spectral assay libraries directly from the DIA data in MetaboDIA (right 
side of Figure 10). This alternative was deemed possible since 
putative molecular formulae can be assigned solely using MS1 data 
alone. The only drawback in comparison to the DDA-based library is 
the lack of assurance in the precursor-fragment specificity, and we aim 
to test the hypothesis that co-fragmentation spectra are potentially less 
reproducible across the samples (in large-sample settings). In this 
pipeline, we build the consensus spectral library in the same way as 
the default (DDA-based) pipeline, with the exception that we apply an 
additional de-isotoping process to the MS/MS (pseudo) spectra as DIA 
allows co-fragmentation of precursor isotopes. Again, the caveat of this 
DDA-free pipeline is that precursor-fragment grouping occurs without 
completely resolving the ambiguity in the mapping (e.g. DIA-umpire 
output). The consensus library is built purely rely on the reproducibility 
of the MS/MS fragments across the samples. Therefore, the pipeline is 
recommended only for large-sample data analysis. See results section 
3.3 for comparative evaluation of final quantitative data. 
3.2.7. Differential analysis of MS1- and MS/MS-based quantitative 
data. 
We used mapDIA [17] for all differential expression analysis in this 
work, a software tool originally developed for the analysis for DIA-MS 
data for proteomics data analysis. It considers fragment-level peak 
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area values as repeated measure of the abundance of the 
corresponding peptides and proteins in the downstream statistical 
analysis, and aggregates these fragment-level data into peptide- or 
protein-level statistical summaries. We used mapDIA (version 3.0.1) to 
analyze the quantitative data by considering the CIUs as “protein”, and 
the fragments as “peptides”. For the analysis, we combined the output 
from positive and negative modes and ran mapDIA with “independent 
design” and “level 2 analysis” option. We turned off the filters for 
“minimum fragments per peptide” and “minimum peptides per protein” 
to prevent removal of compounds with single fragment. For group-to-
group statistical comparisons, each fragment was included for 
statistical analysis if there are at least 5 samples with non-missing data 
in both comparison groups. Then the compounds were selected with 
score thresholds associated with 5% FDR. See Appendix 2,3 for 
mapDIA parameter settings. 
3.2.8. Spectral similarity score for comparison of MS/MS spectra. 
To compare MS/MS spectral similarity, we adjusted normalized dot 
product (left side in the equation) by the percentage of the matched 
peaks (right side): 
The score ranges from 0 to 1, where 0 means no matched 
peaks and 1 means every peak is perfectly matched with the same 
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relative intensities on both sides. In detail,  is the intensity of the i-th 
peak in the query spectrum (Q), and  is the intensity of the j-th peak in 
the library spectrum (L). m is the number of peaks in the query 
spectrum and n is the number of peaks in the benchmark (library) 
spectrum.  and  are the intensities of matched peaks from query and 
library spectra, respectively. k is the number of matched fragment pairs 
between spectra. When we perform verification of CIUs by 
benchmarking MS/MS spectrum against the NIST, MassBank, 
LipidMaps/LipidBlast libraries, we first removed the spectra with low 
mass accuracy peaks (resolution poorer than <3rd decimal place) and 
converted the intensities to relative intensity. The resulting version of 
each library contained 95794 (NIST), 11774 (MassBank), and 212516 
(LipidBlast) MS/MS spectra, with positive and negative mode data 
combined.
3.2.9. MS-DIAL analysis. 
We analyzed the AMD DIA data in the positive and negative ionization 
modes using MS-DIAL program (version 2.0.2) [19] with the 
combination of filtered LipidBlast [49], NIST [50] and MassBank [33] 
MS/MS libraries (used for validation above). See the comparison and 
parameter setting in the Appendix 4.
3.3. Results and Discussion
3.3.1. Overview of MetaboDIA
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Figure 10 shows the overall workflow of MetaboDIA. The workflow 
starts with ion chromatogram extraction of precursor and fragment ions 
using widely accepted algorithms such as XCMS/CAMERA[22, 38] 
and DIA-Umpire[18]. Once MS1 and MS/MS data are prepared, the 
first step performs putative molecular formula identification by querying 
monoisotopic mass of each MS1 peak cluster against known 
databases of molecular formulae and their exact mass values. Here we 
assign all possible molecular formulae whose monoisotopic mass lies 
within a user-specified mass tolerance around each Precursor Ion peak 
in individual samples, considering various adduct ions of concurrent 
charge state (see Experimental Section 3.2). We next perform 
retention time (RT) alignment of each peak feature across the samples. 
Each RT-aligned consensus MS1 peak feature becomes the base unit 
of the spectral library, which we call compound identification unit (CIU) 
here after. CIUs are characterized by average precursor m/z value of 
its monoisotopic peak and RT range (Figure 12a). 
Here, monoisotopic mass search typically reports more than one 
formula, and thus we keep a counter for each formula and record the 
most frequently occurring formula across the samples as the 
representative molecular formula for each CIU. By construction, each 
CIU is ideally a template for a unique compound, but it is often 
annotated by multiple molecular formulae at this stage and precise 
compound name can only be assigned once an external source based 
on authentic standard confirms the MS/MS spectra.
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Figure 12. (a) Consensus library building step relies on RT-
based alignment of MS1 signals across samples. At this stage, 
the signals sharing the same m/z value and precursor charge 
state can be separated into different compound identification 
units by a sufficiently long gap in elution profiles (RT). (b) For 
the CIUs with MS/MS spectra, fragment peaks are collected 
from the DDA data (or DIA data in the alternative pipeline) and 
the peaks present in a minimal number of collected spectra (e.g. 
50%) were admitted into the spectral library. 
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a Putative molecular formula assignment
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The novelty of MetaboDIA is how we associate each CIU with a 
consensus MS/MS spectrum. In this step, we first impose minimal 
consistency criterion for precursor-fragment pairing across the samples 
and further apply a cross-sample reproducibility filter to each fragment 
ion. Hence the resulting consensus spectrum is ensured to replicate 
the spectra in individual samples well before entering it into the library 
(Figure 12b). This filter guarantees that the final peak area/height data 
are extracted for the most reproducibly occurring fragment ions for the 
compound designated to each CIU.
Regardless of the strict filtering process, however, it is still 
possible that a single CIU may represent multiple isobaric compounds. 
Therefore, these entries eventually need to be verified by a validation 
experiment using authentic standards or by use of an existing library 
(e.g. NIST 2014 library) generated from pure standards. To address 
this, MetaboDIA also provides a highly specific scoring metric, a 
modified form of normalized dot product, to benchmark each MS/MS 
spectrum against the aforementioned MS/MS libraries (see spectral 
similarity score in Experimental Section 3.2). In our experience, score 
0.5 or higher tends to give high confidence match in the query, and 
thus the compounds scoring ≥0.5 are considered as validated by a 
reference spectrum in our workflow. 
Figure 11 shows an example CIU representing L-arginine 
(C6H14N4O2, monoisotopic mass 174.111676) with nearly perfect 
replication of a spectrum in MassBank, demonstrating the full 
information structure of CIUs in the reported spectral assay library. 
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Note that this CIU had two other competing molecular formulae 
(C9H18OS and C11H14N2, monoisotopic mass 174.107836 and 
174.115698, respectively) that were virtually indistinguishable by 
monoisotopic mass alone. 
3.3.2. Analysis of marine algae data set 
We first evaluated the MetaboDIA workflow using a marine algae data 
set provided by the authors of the MS-DIAL paper[19]. In the original 
paper, the authors reported identification of >1,000 lipids by MS-DIAL 
with LipidBlast library in 10 different species using SWATH-MS with 21 
Da isolation windows (without the data produced from the runs with 65 
Da isolation window). We analyzed the data from both positive and 
negative ion mode scans using MS-DIAL in lipidomics mode with 
suggested options. In parallel, we also analyzed the same data with 
MetaboDIA, which built a customized spectral assay library from the 
DDA data in each species and quality control (QC) runs.
MS-DIAL reported a spreadsheet with thousands of rows as 
expected, but a large fraction of reported compounds was identified 
based on the scoring of MS1-level data, not MS/MS. In our MS-DIAL 
analysis of the positive and negative ion mode data, for instance, 2779 
compounds were reported in at least 3 SWATH-MS runs (treating each 
technical replicate as one run). However, only 673 of them (24.2%) had 
matching MS/MS spectra from their reference library, presumably the 
LipidBlast library. Moreover, when we scrolled through the MS/MS 
spectra, hundreds of experimental spectra showed poor match quality 
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to the reference library spectra. Upon observing this, we decided to 
compare the two pipelines only for the reported compounds with MS/
MS evidence as there are many confounding variables for directly 
comparing the identified compounds from both methods.  
3.3.2.1. DDA-based library spectra do not emulate fragmentation 
patterns in reference libraries 
After narrowing down the compounds for comparative evaluation, we 
acquired 673 and 1041 compounds with MS/MS matching in MS-DIAL 
and MetaboDIA, respectively. Note that MS-DIAL uses MS1-based 
quantification and does not quantify fragment ions. Meanwhile, the 
putative formula assignment and MS/MS library-building process in 
MetaboDIA is based on strict mass tolerance cutoffs (30 ppm for MS1, 
40 ppm for MS/MS). By contrast, the proposed data extraction 
parameters in MS-DIAL are as wide as 0.025 Da and 0.25 Da for MS1 
and MS/MS data, respectively (see Supplementary Information of 
Tsugawa et al[19]). In MetaboDIA, we built the customized library from 
the DDA data for all 10 species, requiring that each fragment ion peak 
appear in at least 3 of the 43 DDA-MS runs. The seemingly low 
reproducibility filter was necessary in this particular data set since 
many lipids were uniquely identified in single or a few species, 
consistent with the finding in the original paper, and each species was 
analyzed in at least 3 technical replicates. 
The resulting spectral library contained 751 and 290 CIUs with 
MS/MS spectra in positive mode and negative mode data respectively. 
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We emphasize that these libraries are built from DDA-MS data, hence 
there is little ambiguity in precursor-fragment mapping. However, only a 
modest proportion of the CIUs could be validated using the LipidBlast 
library, even after adding two more libraries in the end (NIST 2014, 
MassBank). 446 and 181 CIUs (59.4% and 62.4%) had completely no 
shared peaks with any spectra in the combined reference library. This 
implies that, had we not deliberately built a customized library, a large 
proportion of MS/MS data would have been discarded in the pipelines 
relying on reference libraries. In summary, the observed variability of 
MS/MS spectra between experimental data and the reference library 
suggests that a customized library built from the users’ own data is 
essential to prevent loss of MS/MS data for both identification and 
quantification purposes.  
3.3.2.2. Fragment ion data offers repeated measures of abundance 
with comparable coefficient of variation to MS1 measurements 
Using the customized DDA-based library, we quantified fragment ions 
across 43 SWATH-MS runs as well as the quality control runs. Using 
compounds with MS/MS evidence, we next compared the quality of 
quantification for MS1 Precursor Ion data from MS-DIAL and 
MetaboDIA, and MS/MS fragment ion data from the latter. Figure 13a 
shows the coefficient of variation (CV) across technical replicates in 
MS1 peak area data for 673 compounds in MS-DIAL (with MS/MS 
evidence), DDA-MS1 intensity data for 1041 compounds from 
MetaboDIA (with MS/MS evidence), and DIA-MS/MS intensity data for 
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708 compounds from MetaboDIA. Comparing the three results, CV 
values were larger for the MS/MS intensity data than the other two 
MS1-based quantification methods. However, most CV values were 
below 20% in all three methods. The compounds with >10% CV in the 
MS/MS data tended to be on the ones with low DDA-MS1 intensity 
values as expected, for which the standard deviation of the CV formula 
is often estimated coarsely when the sample size is small.
We note that the CV values in the MS/MS intensity data are 
median CV values of all fragments for each compound, and thus the 
plots indicate that not all extracted MS/MS intensities are suitable for 
quantification. Therefore careful selection of fragments for final 
quantification is needed for robust quantitative analysis, a variant of 
which is already implemented in published algorithms such as mapDIA 
developed by our group[17]. Despite some caveats, the overall results 
suggest that, with rigorous filtering of fragments, MS/MS data has a 
great potential to provide additional quantitative information of a 
comparable quality to MS1 intensity data. As we illustrate in the next 
data set, the availability of repeated measurements of each compound 
can be an advantage over MS1 data, which often improves the 
statistical power to detect signals of a smaller effect size[17].  
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Figure 13. (a) Coefficient of variation in 10 algae species and quality 
control samples in the marine algae data set. In each sample set (with 
3-4 technical replicates), the CV distributions are shown for MS1 peak 
area data from MS-DIAL, MS1 intensity data from MetaboDIA, and MS/
MS intensity data from MetaboDIA (DDA-based library). (b) The Venn 
diagram of shared and unique CIUs in the DDA-based and DIA-based 
libraries built by MetaboDIA. Spectral similarity score distribution 
suggests that more than half of MS/MS spectra score above 0.5. (c) 
Fold change values (log base 2) computed in all possible species-to-
species comparison using the two libraries. Even though the two 
libraries report different sets of fragments, mapDIA chooses reliable 
fragments within each data set, contributing to similar or identical fold 
changes in many comparisons.
3.3.2.3. Spectral libraries built directly from DIA data may not be 
reliable in small sample analysis 
Since molecular identification does not rely on database searching, the 
only benefit of DDA-based library building is in the specificity of 
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the possibility of building a MS/MS library directly from the DIA-MS 
data. The idea is straightforward: putative molecular formulae are 
assigned using MS1 data from the DIA runs, and precursor-fragment 
mapping is filtered based on the correlation of XICs between MS1 and 
MS/MS data, as is often done in the targeted extraction steps of 
existing DIA-MS data processing tools. 
To do this, we have used the precursor-fragment pairing 
algorithm in DIA-umpire[18] in each sample, and used MetaboDIA to 
align precursor-fragment pairs across the samples by RT, requiring that 
the precursor-fragment pairs appear in at least 3 DIA runs when 
building the MS/MS library. We then compared the resulting DIA-based 
libraries in positive and negative modes to the corresponding DDA-
based libraries. 
Figure 13b shows the overall comparison of DDA- and DIA-
based libraries. The libraries shared 537 CIUs, of which 333 (62%) 
scored spectral similarity score 0.5 or above. This relatively low overlap 
probably comes from the lenient reproducibility requirement, i.e. 
appearance in as few as 3 technical replicate runs. This suggests that 
building spectral libraries directly from DIA data is difficult in small-
sample analysis settings, in which generation of DDA data for a 
customized library building does not incur too much cost anyway. 
However, we show in the next data set that this difficulty can be 
overcome in large-sample analysis settings. 
Surprisingly, the DIA-based library tended to have fewer MS/MS 
peaks than the DDA-based library in this data set. The observation is 
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likely due to the lack of specificity in precursor-fragment pairing, in 
which some fragments were lost due to the possibility of assignments 
due to multiple precursors in the DIA-umpire pipeline. Despite the 
discrepancy in the libraries, major peaks in each CIU tended to be 
shared, and the extracted quantitative data using both libraries were 
also highly correlated in terms of relative quantification. Figure 13c 
shows that the fold change estimates from pairwise comparisons of 10 
algae species, obtained from the mapDIA software with default 
parameters for fragment selection, were consistent between the two 
extractions (Section 3.3.2.4). In sum, building customized MS/MS 
libraries from DIA runs seems to carry high risk of poor precursor 
specificity in analysis with a small sample size, but quantitative analysis 
with careful selection of fragment ions may reduce the risk even in the 
small sample analysis setting. 
3.3.2.4. Remarks on the spectral library construction using DDA 
data as source
Typically, MS1 peak features with the same m/z values of the 
monoisotopic peak appear numerous t imes at d i f ferent 
chromatography times. These are potential signs of isobaric 
compounds, and we thus record them separately. To address this, we 
carried out the following alignment procedure:
• Extend 6 seconds (used defined) on both ends of the RT range of 
MS1 peak features in each sample.
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• Collect all the MS1 peak features with same identified formulae and 
charge state across the samples.
• List the MS1 peak features and align their RT intervals to identify the 
RT region with the most frequently occurring elution profiles. We also 
define the range between the minimum start times and the maximum 
end times of MS1 peak features covering the region as alignment 
region (AR) (call this Step D). 
• The above steps create three possibilities:
(1) If there is a single AR, record the interval in the alignment 
results and remove the MS1 peak features covering the region. 
Then the program returns to Step D unless the list of peak 
features is empty.
(2) If there are two or more such regions in Step D and the ARs do 
not overlap, record each region as a separate CIU in the 
alignment results and remove all peak features used in this 
alignment step. The program returns to Step D unless the list of 
elution profiles is empty.
(3) If there are two or more ARs in Step D and there is overlap in 
the RT range of different ARs, merge and export the overlapping 
ARs and remove the MS1 peak features covering the merged 
AR. Then program returns to Step D unless the list of elution 
profiles is empty.
• The alignment steps are applied to all identified formulae and charge 
state
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• After the alignment step, export quantification of the CIUs to a tab 
delimited file with each row representing one CIU, i.e. a formula with 
charge state and RT range. In addition, export the number of isotope 
peaks in the peak features that are aligned in each CIU.
3.3.3. Analysis of AMD data set
To demonstrate MetaboDIA in complex clinical samples, we applied the 
workflow to a clinical metabolomics data set consisting of 20 choroidal 
neovascularization cases (CNV-AMD), 20 polypoidal choriodal 
vasculopathy cases (PCV), and 20 healthy controls (see Experimental 
Section 3.2) [45]. Each sample was first analyzed by DDA, followed by 
the SWATH acquisition with 25 Da isolation windows on an AB Sciex 
TripleTOF 5600+ system coupled to reverse phase liquid 
chromatography with positive and negative ion mode scans separately 
(see Experimental Section 3.2 for instrument setup details). For the 
purpose of benchmarking, we again evaluated spectral library building 
and MS/MS-based quantification from MetaboDIA in comparison to the 
analysis using MS1-based quantification data in both MetaboDIA (using 
DDA data) and MS-DIAL software (using DIA data).  
3.3.3.1. Customized spectral library building from DDA data
We first built spectral libraries from the DDA data in positive mode and 
negative mode analysis separately. The DDA-based library for positive 
and negative mode data contained 982 and 847 CIUs respectively. 
These CIUs were assigned molecular formulae with monoisotopic 
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mass searching of MS1 data. After RT alignment, each CIU must have 
MS/MS data (with paired precursors) in at least one third of 60 samples 
(plus QCs), and each fragment ion must appear at least 50% of the 
samples with MS/MS data. The two conditions impose markedly more 
stringent reproducibility criteria in library building than the process in 
the marine algae data set, which is made possible with the availability 
of 60 DDA runs. For precaution, however, we clearly indicate in how 
many samples each spectrum was reproducibly observed in the library 
(in the putative formula Section 3.2.5.1). 
In the resulting spectral library for positive and negative modes, 
merely 156 and 81 CIUs were matched to the reference library 
combining NIST, MassBank, and LipidBlast (spectral matching score 
0.5 or above). In our default validation, we queried each CIU against all 
reference MS/MS spectra associated with the putative formulae 
assigned by MS1. When we did not limit the search space to those 
sharing the same formulae, putative formulae were validated in 109 
and 61 CIUs only in positive and negative modes respectively. This 
observation suggests that the monoisotopic mass filter of MS1 data 
improves the validation rate by reference libraries, highlighting the 
importance of precursor data along with MS/MS data in compound 
identification process. The resulting library contained a variety of 
metabolites including amino acids, fatty acids, and phospholipids (the 
library files available in the software release). 
Although some CIUs had reference library validation, the library 
also contained many CIUs that either scored poorly (score below 0.5) 
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or had no matching peak at all against any library spectra (score 0) 
(Figure 14a). One possible source of this phenomenon is that the 
peaks present in DDA data could not be replicated as consistently in 
DIA runs as in DDA runs. This is possible because more Precursor Ions 
are fragmented within the same isolation window, which not only 
causes fragment ion interference but also intensity suppression of 
individual fragments. In this scenario, our reproducibility requirement 
(20 or more samples, 50% in available MS/MS spectra) can easily filter 
those fragments out. More importantly, many putative formulae 
assigned by monoisotopic mass search of MS1 data were not part of 
the reference MS/MS libraries – of 1829 CIUs, MS/MS records were 
missing for as many as 585 molecular formulae in the combined 
reference library. As in the previous data set, we could retain these 
consensus MS/MS spectra in the library and quantified them by MS/MS 
in our workflow. However, compound assignment in these CIUs should 
be given further scrutiny.  
3.3.3.2. Fragment ion quantification provides high quality 
quantitative data in complex samples
We next compared the quality of quantitative data from different data 
extraction methods, including MS1 peak area data from MS-DIAL 
(using the rows in the data matrix with library validation), MS1 intensity 
from MetaboDIA (records with MS/MS only), and MS/MS intensity from 
MetaboDIA. Since we did not have quality control runs or biological/
technical replicates in this experiment, we measured the coefficient of 
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variation using the data for the 20 healthy samples, pretending as if 
they are biological replicates. We treat this CV measure “pseudo” CV 
hereafter, acknowledging that there is inter-individual variation captured 
in the numerator part of the CV formula (standard deviation divided by 
mean of log2 intensity data).
Figure 14 summarizes the result. There were 721, 982, and 883 
quantified compounds in the three versions of positive mode data with 
MS/MS evidence, respectively. MS-DIAL reported very few compounds 
with MS/MS evidence in the negative mode data, and therefore we 
used the positive mode data for comparison between the two software 
packages. Contrary to our expectation, the pseudo CV values were 
generally smaller in this data set than the marine algae data set. We 
attribute this to the availability of 60 samples in this data set, which 
tends to shrink the sample standard deviation. The CV values were 
again the smallest in the MS1 intensity from MetaboDIA among the 
three options, and most values were below 20% CV (Figure 14b). 
Using the quantitative data obtained by each extraction method, 
we performed differential expression analysis to identify metabolites 
differentiating the three groups (CNV, PCV, and healthy controls) using 
the mapDIA software package [17]. We first note that the fold changes 
for all pairwise comparisons were highly consistent between MS1 
intensity and MS/MS intensity within the MetaboDIA extraction (Figure 
14c).
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Figure 14. (a) DDA-based library built by MetaboDIA. The counts are 
the number of CIUs with different score ranges. The CIUs in the red 
fraction do not have any MS/MS spectra associated with molecular 
formulae in our combined reference library. (b) Pseudo CVs in the 
metabolite quantification using three different extraction methods: MS1 
peak area data from MS-DIAL, MS1 intensity data from MetaboDIA, 
and MS/MS intensity data from MetaboDIA (DDA-based library). The 
data shown are from the positive ion mode data set. (c) Differential 
expression output (log2 fold change) from mapDIA between CNV, PCV, 
and healthy controls. Red and blue symbols are significantly altered 
metabolites with positive and negative log2 fold changes, whereas gray 
symbols are the metabolites that were not statistically significant in any 
comparisons.
Comparing the results between MS-DIAL and MetaboDIA was 
difficult because there are various factors influencing the input data to 
the statistical analysis. First, compound assignment process is 

























































composite score from both MS1 and MS/MS data and the molecular 
formulae are assigned from a different background list. The latter 
discrepancy was also observed in the recent comparison between MS-
DIAL and Met-DIA. Second, MS-DIAL performs imputation for missing 
peak area data, which we have no control to disable as a user. Even if 
we limit the comparison to the compounds with 95 MS/MS validated 
compounds with RT difference less than 30 seconds between the two, 
the within-sample correlation of quantitative data between the two 
versions of quantitative data was on average at most 0.47 (95% range: 
0.29 – 0.61), suggesting substantial difference in the overall 
quantification output. We therefore refrained from further direct 
comparison of quantitative data between the two methods. 
3.3.3.3. Differential expression analysis of CNV, PCV and healthy 
controls
The mapDIA analysis of MS/MS data revealed that both PCV and CNV 
patients had higher serum concentration of glycerophospholipids[51], 
covalently modified amino acids and di/tri- peptides[52], a variety of -3 
and -6 polyunsaturated fatty acids and their derivatives and a few 
carnitine species in this data set. Figures 15a through 15d show the 
serum concentration of phosphatidylcholine, pinolenic acid, 
docoxahexaenoic acid, eicosatetraenoic acid, which are mostly 
elevated in both AMD groups, with the exception of pinolenic acid (up 
in CNV patients, but not in CNV). The corresponding figures for the 
same set of compounds in DIA-based library extraction can be found in 
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Figure 16a through 16d, which shows identical patterns across the 
compounds. The overall quantitative trend for 197 significantly altered 
compounds can also be seen in the Figure 17.
Interestingly, although DHA, along with and eicosapentaenoic 
acid (EPA) have been shown to be associated with lower risk of 
neovascular AMD for Caucasians in the previous literature[53], the 
figure clearly shows that DHA was consistently elevated in both AMD 
patients over healthy controls in this study population consisting of 
relatively older Chinese subjects. Meanwhile, a few compounds with 
reference library validation (or without) were also differentially 
expressed between the CNV and PCV patients, but they were mostly 
reaffirming the compounds that were uniquely differential (from the 
controls) in one of the two AMD groups. In sum, overall metabolomic 
difference was less pronounced between the two subgroups than the 
difference between cases and controls. 
While biological implication and validation of quantification 
should be made in a separate follow-up study with prospective design, 
these figures show that the MS/MS intensity data replicates the 
consistent patterns observed in MS1 intensity data. More importantly, 
when we performed the same quantitative comparison using the MS1 
data with mapDIA, the statistical significance values (posterior 
probability of differential expression) and associated FDR were 
substantially conservative this time, yielding merely 24 (FDR 5%) 
compounds. As a result, the case-to-control or PCV-to-CNV differences 
that were statistically significant in the MS/MS-based analysis were no 
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longer significant at the same type I error (false discovery rate), despite 
the consistency in the fold changes between the two versions of data. 
Given that we have a modest sample size (20) representing each 
group and measurements are missing in some samples, this shows 
that the downstream statistical analysis benefited significantly in terms 
of statistical power from the availability of repeated measurements via 
MS/MS-based quantification. However, the caveat is that not all 
statistically significant compounds are true positives, and therefore 
further validation experiments are necessary to definitively attribute the 
increased number of reported compounds to improvement in power.  
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Figure 15. (a-d) Boxplots showing the distributions of MS1 intensity 
and MS/MS intensity data for phosphatidylcholine, pinolenic acid, 
docoxahexaenoic acid, eicosatetraenoic acid in the three comparison 
groups. The data were extracted using the DDA-based library. Most 
fatty acids and glycerophospholipids were significantly elevated in the 
two patient groups compared to the healthy control, whereas some 
were significantly elevated uniquely in each AMD subtype in mapDIA 
analysis. Green, red, and blue boxes correspond to healthy controls, 






























































Figure 16. Boxplots showing the distributions of MS1 intensity and MS/
MS intensity data for phosphatidylcholine, pinolenic acid, 
docoxahexaenoic acid, eicosatetraenoic acid in the three comparison 
































































Figure 17. (a) Heatmap of MS1 intensity values from MetaboDIA. (b) 
Heatmap of summary MS/MS intensity values acquired by the DDA-
based library from MetaboDIA (quantitative summary by mapDIA). 
3.3.3.4. Alternative workflow for DIA-based library yields similar 
quantitative downstream analysis results
Following the example in the algae data set, we again tried to build a 
spectral library and performed quantitative analysis using MS/MS data 
solely based on DIA-MS data. DIA-based library contained a similar 
number of CIUs to that of DDA-based library (Figure 1ba). As in the 
DDA-based library, not all CIUs appeared in tens of samples, and we 
reiterate that the count of 1780 CIUs does not mean that we have solid 
MS/MS evidence replicating fragmentation patterns in reference 
libraries for all 1780 compounds. When we compared these spectra 
against the reference library, once again as few as 146 CIUs were 
reliably verified (score 0.5 or above). When we compared the DDA-
based and DIA-based libraries, however, a majority of library entries in 
the DIA library could be replicated with spectral similarity score above 
0.5 (Figure 18b). Overall, this proves that the majority of our 
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experimental MS/MS spectra do not reproduce the same fragmentation 
patterns in the reference library under our instrument setup.
We next used the resulting library to extract quantitative MS/MS 
data and performed differential expression analysis for the three 
groups. Comparing the fold changes in pairwise comparisons, we 
found that the majority of the compounds had highly similar fold change 
values (Figure 18c). Both results suggest that our reproducibility-
driven consensus spectral library building can yield a spectral library of 
comparable quality to the DDA-based library in large-scale 
metabolomics setting. However, this approach still does not guarantee 
removal of contamination by fragments from co-eluting ions, and 
therefore a more systematic approach to establish robust precursor-




Figure 18. (a) DIA-based library built by MetaboDIA. The counts 
are the number of CIUs with different score ranges. The CIUs in 
the red fraction do not have any MS/MS spectra associated with 
molecular formulae in our combined reference library. (b) 
Differential expression output (log2 fold change) from mapDIA 
between CNV, PCV, and healthy controls using MS/MS intensity 
data extracted with the DIA-based library. Red and blue symbols 
are significantly altered metabolites with positive and negative 
log2 fold changes, whereas gray symbols are the metabolites 
that were not statistically significant in any comparisons.  (c) The 
Venn diagram of shared and unique CIUs in the DDA-based and 
DIA-based libraries built by MetaboDIA in the AMD data set. 
Spectral similarity score distribution suggests that a majority of 
MS/MS spectra, especially the ones found with high frequency 
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3.4. Discussion and Conclusion
In summary, MetaboDIA provides a unique workflow to maximize the 
utility of MS/MS data for metabolite identification and quantification in 
the context of untargeted metabolomics. Our workflow is clearly 
different from the MS-DIAL tool for untargeted data extraction as the 
focus of MetaboDIA is in building customized spectral libraries for MS/
MS-based relative quantification. The library data structure reflects the 
uncertainty in MS1 molecular formula assignment by calling it putative 
assignment and listing all putative formulae with their respective 
frequency of appearance in the user’s data first. This ambiguity will be 
resolved only when external MS/MS-level evidence (e.g. reference 
libraries) shows identical fragmentation patterns to the empirical 
spectra. 
The advantage of this workflow is that the user retains the 
consensus MS/MS data that frequently appear in their data set, 
although no existing MS/MS spectra in reference libraries may validate 
them. The utility of this approach is appreciable considering that the 
reference MS/MS libraries containing more than hundreds of 
thousands of records validates merely a few hundred compounds per 
sample at best in our experience. As such, storing MS1 and MS/MS 
evidence with the distinction for the compounds with solid validation by 
MS/MS and the ones without, is an important feature for any 
informatics suite for metabolomics application. 
Although MS1 data remains the major anchor for identification 
and quantification of a large number of molecules (i.e. without solid 
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MS/MS data), our work clearly demonstrated the utility of MS/MS data 
as a source of relative quantification in two independent data sets. This 
is one of the first applications using DIA-MS where a customized 
spectral library is constructed to avoid loss of data. The analysis of the 
two data sets suggests that the quality of MS/MS-based quantification 
is comparable to that of MS1-based quantification in terms of CVs, with 
the added advantage that MS/MS data provide repeated measurement 
of relative quantity for metabolites and allows for improved sensitivity 
for differential expression analysis. 
While our tool is one of the earliest to enable MS/MS-based 
quantification of small molecules, there are various aspects in which 
MetaboDIA can be improved. First, although we imposed stringent 
reproducibility criteria in the library-building step, we have yet to 
investigate the possibility of a more streamlined quality control 
procedure other than sample-to-sample reproducibility and RT 
alignment, especially in terms of uniqueness of each fragment in the 
assigned compound. Second, although our pipeline makes efforts to 
avoid multiple compound names assigned to a single peak cluster by 
stepwise separation (molecular formula and RT separation), the current 
selection of best representative formula is selected by the frequency of 
observation in the given sample set, and we can further reduce this 
ambiguity by reconciling MetaboDIA-built libraries with reference 
libraries. 
Last, but not the least, our current implementation of MS/MS-
based quantification is not fully targeted extraction as we used the first 
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two quality tiers of data reported from the signal extraction module of 
DIA-umpire. This portion of data has a set of MS/MS data for the 
precursors with at least two isotopes appearing in the MS1 data, for 
which there is no ambiguity in charge state determination. However, 
there are a handful of MS/MS peaks that are not clearly associated 
with a Precursor Ion in SWATH scans, and thus expanding the 
coverage to those MS/MS peaks by targeted extraction, independent of 
MS1 data, will increase the volume of extracted data and allow us to 
work with a reduced number of missing data. This will be an easy 
extension given that there are multiple software pipelines such as 
Skyline [54] and OpenSWATH [55] as well as MetDIA [20] that can 
perform targeted extraction. We nevertheless suspect that fully 
targeted extraction still carries the risk of incorrect fragment selection 
when unique MS/MS fragment ions are rare for a compound (e.g. 
lipids) and its precursor abundance is low. We leave this for further 
investigation in the future.  
In this work, we also attempted to build spectral libraries directly 
from the DIA data alone, where precursor-fragment map is not 
definitive. While this carries the risk of incorrect association between 
the two levels of data, we observed that the internal library built from 
DDA data was highly consistent with the one built from DIA data in 
large-sample analysis settings, yielding nearly identical MS/MS spectra 
for a few hundreds of compounds. We conjecture that our strict 
reproducibility criterion produces library spectra of a reasonable quality, 
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but more future work will be needed to establish a systematic means to 
reinforce the correct pairing of fragments to their parent compound. 
The R package MetaboDIA is freely available for academic use 
(Apache 2.0 l icense) at SourceForge repository, https://
sourceforge.net/projects/metabodia/. The raw mass spectrometry data 
for DDA and DIA experiments is available at MetaboLights repository 
(MTBLS417). 
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Chapter 4: Discussion and Conclusions
4.1. Summary of the thesis
MS based Metabolomics is becoming a growing topic in clinical 
research field. However, compare to MS-based proteomics, there 
remain limitations in compound identification, data extraction and DIA 
data processing steps. In the two chapters of this thesis, I provided two 
computational approaches that address some of the deficiencies in the 
current bioinformatics pipeline for metabolomics data processing.. The 
MetTailor package [56] addressed the limitations of missing values in 
MS1 based alignment and the inability of existing methods to adjust the 
variation in intensity data along RT. In the MetaboDIA work, we 
developed a novel framework for DIA-MS data processing and analysis 
in metabolomics that constructs customized MS1- and MS/MS-based 
spectral libraries in the context of large-sample analysis DIA data or the 
paired DDA data and also re-extracts MS/MS quantification data from 
DIA data.
4.2. Discussion
4.2.1. Systematic processing of MS1 and MS/MS data
As mentioned in Chapter 2, the first step for data processing is peak 
extraction using MZmine [21] or XCMS [22]. The basic principle of peak 
extraction is identifying of ion chromatograms at the same m/z along 
RT axis. In this step, MS/MS data is always ignored. After peak 
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extraction, cross samples alignment along RT and m/z axis is 
performed followed by normalization and statistical analysis. MS/MS 
data is then mapped to the aligned peak for compound identification. In 
this approach, however, a significant fraction of the MS/MS data is 
unused. Furthermore, after the cross samples alignment, the RT and 
m/z coordinates may be slightly changed for individual sample and it is 
not possible to trace back the original coordinates after the alignment. 
As a result, a lot of MS/MS information may be “lost” due to the inability 
of mapping MS/MS spectrum to its original precursor’s ion 
chromatogram. As discussed in Chapters 1 and 3, MS/MS spectrum is 
the fingerprint of the precursor and it is important for compound 
identification and consensus library building. To the best of my 
knowledge, no algorithm has been reported regarding this aspect. 
Hence there is a need for novel peak extraction algorithms that 
systematically process MS1 precursor together with MS/MS spectrum. 
During the analysis of the MS based metabolomics data, we noticed 
that MS/MS data could aid the extraction of its MS1 precursor. Since 
the MS1 precursor’s m/z and RT coordinates are recorded in the MS/
MS data, these coordinates can be used to locate the ion 
chromatogram of the MS1 precursor and also identify the isotope 
peaks. However, the MS1 precursors without MS/MS information will 
be temporarily ignored.
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4.2.2. Regional noise estimation and isotope identification
In the current algorithms, one challenge is compound identification for 
peak data with low abundance levels, i.e. how to distinguish them from 
in low abundance from the noise in the data. While this requires robust 
estimation of the noise level, existing algorithms use a simple minimal 
intensity cutoff for the entire data and simply remove all peaks below 
the cutoff. However, the background noise level may vary along RT and 
m/z. An advantage of MS/MS aided approaches is that we can 
estimate the regional noise level around the MS1 ion chromatograms 
(not uniform across the entire m/z~RT space). Therefore this approach 
is capable of detecting low abundance compounds and more isotope 
peaks. With the isotope patterns, we can deconvolute the charge state 
accurately and assign putative molecular formulae. After this step, 
every MS1 ion chromatogram will have an isotope peak cluster, 
putative molecular formulae and corresponding MS/MS spectrum. I 
name it MS pair in short. 
4.2.3. Cross sample alignment and missing value recovery 
Next, similar to the alignment step in MetaboDIA, the MS pairs are 
aligned across the samples with predefined tolerance in RT and m/z. In 
this step, there will be a number of missing values in the data since the 
precursors without MS/MS information are ignored at this stage. To 
impute the missing values, we can re-extract the MS1 data at the 
aligned RT and m/z. However, the MS/MS data will be missing for 
these recovered peaks. 
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4.2.4. Compound identification and consensus spectral library 
construction
During the alignment step, we can also build consensus MS/MS library 
using the algorithm in MetaboDIA. Comparing with the current 
methods, this approach can fully utilise MS/MS data in both MS1 peak 
detection and consensus library building. Therefore, the compound 
identification and quantification can be more accurate. However, if a 
compound is not selected for fragmentation in any of the samples, its 
information will not be extracted, either. To minimise this limitation, a 
large sample size is required, or we can apply the existing algorithm on 
the remaining data after MS/MS aided extraction.
4.2.5. Separation of isobaric compounds
Isoforms are defined as different compounds with the same molecular 
formula but different structures. They are very common in 
metabolomics, especially in the lipidomics studies. It is still a main 
bottleneck to identify and separate the isoforms when they are co-
eluting or very near in RT since it is not possible to separate them by 
MS1 ion chromatogram. However, under the assumption that the MS/
MS fragment patterns are different for the isoforms. supervised or 
unsupervised clustering methods can be applied on the MS/MS data to 
identify the potential isobaric compounds. We can implement an 
additional step after the alignment to separate the potential isoforms. 
The limitations of this step are: i) In DDA mode it is not likely to have 
 91
MS/MS for every sample; (ii) In DIA mode there is still a lack of tool to 
extract MS/MS data quality with high accuracy.
4.2.6. Robust MS/MS data extraction for DIA-MS metabolomics
As discussed in Chapter 1, in DIA metabolomics, there is a need for a 
data extraction tool designed specially for metabolomics. The signal 
extraction module of DIA-Umpire extract the precursor-fragment pairs 
based on the correlations in ion chromatograms. It finds the most likely 
precursor-fragment pairs and it is possible that there are false 
discoveries. In proteomics, with the help of MS/MS-based peptide 
identifications, the risk of false identification is significantly reduced. 
However, there is a lack of comprehensive MS/MS spectral library in 
metabolomics and quality of the precursor-fragment pairs cannot be 
guaranteed. To ensure the MS/MS extraction quality, a novel algorithm 
is required to filter the MS/MS fragments, estimate the number of 
precursor that the MS/MS fragments are from and then construct the 
precursor-fragment link. For example, we can calculate the correlation 
matrix between the fragments and use clustering method to identify the 
fragments with high correlations. These fragments are likely to be the 
ones with best quality. The next step is to identify the corresponding 
MS1 ion chromatograms of each cluster of fragments using the both 
RT range and correlations between the precursor and fragments. A 
high correlation threshold is needed here to ensure the quality of MS/
MS data. The final step is to assign the remaining fragments to the 
precursors. 
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There are three situations in the remaining fragments. 1) A 
fragment is produced by one precursor and the precursor has that 
fragment only. In this case, the corresponding precursor can be 
assigned by the largest correlation between fragment and precursor. 2) 
A fragment is produced by multiple precursors since different 
precursors may produce the same fragments if the chemical structure 
is similar. In this case, the fragment will not be highly correlated with 
any precursor. Then the ion chromatogram of this fragment can be 
estimated by a mixture model of the multiple precursors’ ion 
chromatograms. Expectation-Maximisation algorithm can be used to 
find the proportions and then de-convolute the ion chromatogram and 
assign the fragment to the corresponding precursors with the estimated 
proportions. 3) The precursor cannot be identified using the above 
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Appendices 
Appendix 1. Parameters for DIA-Umpire extraction module 
(Version 1.284)



























































































LABELS=Ctrl CNV PCV 
SIZE=20 20 20   
### min. max. DE
MIN_DE= .01
MAX_DE =.99
### Contrast matrix for group comparison
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CONTRAST=
- 0 0 
1 - 0
1 1 -

















L A B E L S = C h l a m y d o m o n a s C h r o l l e r a _ U t e x 2 3 4 1 
Chrollera_Utex2805 Chrollera_UtexNC64 Cricosphaera 
Dunaliella Euglena Nannochloropsis Pavlova Pleurochrysis QC 
SIZE=4 4 4 4 3 3 3 3 3 3 9   
### min. max. DE
MIN_DE= .01
MAX_DE =.99
### Contrast matrix for group comparison
CONTRAST=
- 0 0 0 0 0 0 0 0 0 0  
1 - 0 0 0 0 0 0 0 0 0  
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1 1 - 0 0 0 0 0 0 0 0  
1 1 1 - 0 0 0 0 0 0 0 
1 1 1 1 - 0 0 0 0 0 0  
1 1 1 1 1 - 0 0 0 0 0  
1 1 1 1 1 1 - 0 0 0 0  
1 1 1 1 1 1 1 - 0 0 0
1 1 1 1 1 1 1 1 - 0 0
1 1 1 1 1 1 1 1 1 - 0
0 0 0 0 0 0 0 0 0 0 - 
Appendix 4. Data processing parameters of MS-DIAL 
software (v 2.0.2)
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SWATH positive ion mode analysis
Data collection parameters
Retention time begin 0
Retention time end 30
Mass range begin 100








Minimum peak width 5
Minimum peak height 3000
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Peak spotting parameters
Mass slice width 0.1






Sigma window value 0.001
Exclude after precursor TRUE
MSP file and MS/MS identification setting
MSP file E:\MSDIAL \MS-DIAL.msp
Retention time tolerance 0.5
Accurate mass tolerance (MS1) 0.025
Accurate mass tolerance (MS2) 0.25
Identification score cut off 70
Text file and post identification (retention 
time and accurate mass based) setting
Text file
Retention time tolerance 0.1
Accurate mass tolerance 0.01





Retention time tolerance 0.1
MS1 tolerance 0.025
Retention time factor 0.5
MS1 factor 0.5
Peak count filter 0
QC at least filter TRUE
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